先天性心脏病和神经管畸形分子流行病学研究
|
摘要
研究目的
1、探讨父母亚甲基四氢叶酸还原酶(MTHFR)基因C677T、胱硫醚β-合成酶(CBS)基因T833C、环境因素与子代先天性心脏病(CHD)发生的相关性;了解CHD及室间隔缺损(VSD)类型的危险因素;分析危险因素交互作用对VSD发生的影响。
2、筛选单纯性VSD血清标志蛋白并构建其血清诊断模型,为进一步从蛋白质分子水平研究单纯性VSD的致病机理及发展其血清学诊断方法奠定基础。
3、了解广西神经管畸形(NTDs)的基本分布情况,分析环境及行为危险因素。
4、了解广西健康育龄人群MTHFR基因位点突变的分布及其与妊娠结局的联系。
5、了解育龄妇女对NTDs的认知度、增补叶酸的依从性和评价宣教效果,为预防NTDs寻求更有效的干预模式。
研究方法
1、采用1∶1配对病例对照研究方法,对来自广西的115对CHD患儿与对照儿父母进行访谈式调查并抽取父母静脉血3ml作基因型分析,应用PCR限制性片段长度多态性(PCR-RFLP)方法检测MTHFR基因C677T,PCR扩增阻滞突变体系(PCR-ARMS)方法检测CBS基因T833C。对CHD、VSD可能的危险因素进行Logistic回归分析,对筛选出VSD的危险因素之间作交互作用分析,其他数据分析作x~2检验。
2、用CM10芯片检测56例单纯性VSD、85例儿科常见病患儿及23例其它CHD患儿血清,用Biomark Wizard软件分析数据、筛选VSD血清差异蛋白,用BiomarkerPatterns软件构建诊断模型。
3、以入户或电话采访的方式对NTDs和对照的双亲进行调查,获取他们是否暴露于相关环境危险因素的资料,对暴露因素进行Logistic回归分析。
4、抽取早孕妇女静脉血,提取全血DNA,用PCR-RFLP方法检测MTHFR基因位点多态性,再比较其妊娠结局。
5、对参加NTDs知识学习和未参加学习的新婚育龄妇女按调查表内容展开调查,比较两组调查结果;并收集孕妇服用叶酸情况,追踪其妊娠结局。结果用卡方检验和方差分析进行统计分析。
研究结果
1、115例CHD各类型组成VSD 46例、PDA 14例、F4 13例、ASD 6例、其他单纯类型8例、复杂型CHD 28例。广西健康人群的MTHFR基因C/C、C/T、T/T三种基因型构成比分别为64.8%、29.6%、5.7%,C等位基因频率为79.6%,T等位基因频率为20.4%,CBS基因T/T、T/C、C/C三种基因型构成比分别为42.6%、47.8%、9.6%,T等位基因频率为66.5%,C等位基因频率为33.5%。母亲MTHFR基因的C与T等位基因频率比较差异具有统计学意义(P=0.036,OR=1.595,95%CI:1.029～2.471);对于VSD类型,父母组合的MTHFR基因C与T等位基因频率比较差异具有统计学意义(P=0.032,OR=1.724,95%CI:1.043～2.849)。Logistic回归分析表明,母亲孕早期接触农药、妊娠合并症、孕早期感冒、孕期情绪状况、母MTHFR基因型、母CBS基因型为子代发生CHD的危险因素;妊娠合并症、孕早期服中成药、孕期情绪状况、母MTHFR基因型为子代发生VSD的危险因素。交互作用分析表明妊娠合并症与孕期情绪状况、母MTHFR基因型与妊娠合并症、孕早期服中成药、孕期情绪状况间对VSD的发生存在交互作用。
2、25例壮族单纯性VSD与36例壮族儿科常见病儿血清蛋白质谱比较,有7个蛋白成分在VSD血清中高表达,5个蛋白下调;21例汉族单纯性VSD与33例汉族儿科常见病儿血清蛋白质谱比较,有7个蛋白成分高表达,1个蛋白下调;不分民族56例单纯性VSD与85例儿科常见病儿血清蛋白质谱比较,有10个蛋白成分高表达,11个蛋白下调;不分民族56例单纯性VSD与23例其它CHD血清蛋白质谱比较,有9个蛋白成分高表达,16个蛋白下调;不分民族56例单纯性VSD、85例儿科常见病儿与23例其它CHD血清蛋白质谱比较,有25个蛋白成分在三组之间有统计学差异;
3、在单纯性VSD与儿科常见病的血清诊断模型中,完整模型ROC曲线下面积为0.984,预测准确率为96.51%,灵敏度为97.06%,特异度为96.15%,阳性预测值为94.29%,阴性预测值为98.04%,简化模型分别为0.913、88.37%、97.06%、82.69%、78.57%和97.73%,两模型各主要诊断指标比较,除特异度为完整模型优于简化模型外,其它均无统计学差异;在单纯性VSD与非VSD的血清诊断模型中,完整模型ROC曲线下面积为0.988,预测准确率为95.00%,灵敏度为100.00%,特异度为92.42%,阳性预测值为87.18%,阴性预测值为100.00%,简化模型分别为0.948、94.00%、88.24%、96.97%、93.75%和94.12%,两模型主要诊断指标比较无统计学意义。
4、广西七城市NTDs发生率为9.87/万,无脑儿、脑积水占的比例较高,居住地在农村占的比例比城市略高。母亲营养缺乏、患有妊娠并发症、孕期发烧和父亲饮酒是NTDs发生的危险因素。
5、MTHFR基因多态性检测结果为野生基因型59.5%,杂合突变型34%,纯合突变型6.5%,三组基因型围产儿的出生体重和新生儿评分异常率的差别无统计学意义。
6、554名妊娠妇女中,在孕前和孕后3个月每天服用叶酸的83名,占15.0%,怀孕后开始服用的122名,占22.2%,断续服用的27名,占4.9%,未服用叶酸的322名,占57.9%;文化程度初中和初中以下的妇女服用叶酸率较低,分别为33.3%和33.1%,大专的是48.996,大学及以上是65.096。
7、育龄妇女知道叶酸可以预防NTDs的有48%,知道服用叶酸预防NTDs从孕前开始的只有13.4%,计划服用叶酸的只有23%,知道NTDs类型的有15%,知道NTDs发生的可能原因有26.2%,经过宣传讲解后,对NTDs和叶酸的认知率都提高到78%以上;文化程度为初中及以下的知道叶酸可以预防NTDs的只有14.28%,计划孕前开始服用叶酸的只有7.12%,而大学及以上的分别是86.96%,73.91%。
8、服用叶酸组出生缺陷检出率为8.96‰,平均出生体重为3237.0克,早产儿发生率为6.43‰;未服用叶酸组分别为13.33‰、3119.3克和8.50‰,其中平均出生体重的差别有统计学意义。
研究结论
1、母亲MTHFR基因677TT型与子代CHD发生有关,父母双方MTHFR基因677C→T突变与子代VSD发生有关,父母CBS基因833T→C突变与子代CHD无相关性。母亲孕早期接触农药、妊娠合并症、孕早期感冒、孕期情绪状况、母MTHFR基因型为子代发生CHD的危险因素;妊娠合并症、孕早期服中成药、孕期情绪状况、母MTHFR基因型为子代发生VSD的危险因素。不分型CHD总的危险因素与VSD的危险因素不尽相同,交互作用分析提示危险因素共同引起子代VSD发生的过程中,存在着主要由某两个危险因素交互作用影响的可能,亦提示各类型CHD的发生存在相同的情况。
2、单纯性VSD、儿科常见病儿与其它CHD血清蛋白质存在差异,质荷比6441、6640、8570及8700的蛋白质可能是VSD的血清蛋白标志物。
3、两种VSD血清简化诊断模型具有较高的准确性,有较好的应用前景。
4、表面增强激光解吸/电离飞行时间质谱技术是寻找VSD标志蛋白和发展VSD血清学诊断技术的有效工具。
5、为了减少NTDs的发生,育龄妇女除了增补叶酸以外,还应避免暴露于某些环境危险因素。
6、不同地区、不同人群MTHFR基因分布各有特点,存在明显的群体差异,检测得到广西健康人群的MTHFR基因C677位点突变分布可为今后优生保健的健康筛查工作提供依据。
7、育龄妇女对叶酸和NTDs的知晓率较低,叶酸预防NTDs知识尚未得到很好的普及,叶酸利用率较低,通过健康干预使育龄妇女对NTDs的知晓率和叶酸的利用率均显著提高。
Objective
1.To explore congenital heart diseases(CHD) in offspring in association with parental MTHFR gene C677T and CBS gene T833C;To identify the risk factors of CHD and VSD type with Logistic regression;To explore the interaction among the risk factors of VSD type.
2.Using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry(SELDI-TOF-MS) technology to screen serum protein markers,and to construct serum diagnostic model of isolated ventricular septal defect(VSD).As a pilot study,it aims to lay the foundations for investigating the pathogenesis of VSD at protein molecular level,and for developing serum diagnosis technology of VSD.
3.To investigate the general distribution and environmental risk factors of neural tube defects in Guangxi province.
4.To understand corelationship of health women's mutations of the methylenetetrahydrofolate reductase(MTHFR) gene in Guangxi and the MTHFR C677T mutation and pregnancy outcomes.
5.To assess the knowledge of NTDs of the reproductive-aged women and their compliancy about using folic acid.Spread the knowledge about NTDs to the reproductive-aged women and assess the effects.To make the people attach important to taking folic acid and find a more effective intervention model for NTDs preventing.
Methods
1.To investigate 115 pairs case-control children and their parents who came from Guangxi province with 1:1 case-control study,we investigated possible risk factors by questionnaire,parents' blood samples were collected to examine genotype.We adapted PCR-RFLP method to identify MTHFR gene 677 C→T mutation and PCR-ARMS method was used to identify CBS gene 833 T→C mutation.The possible risk factors were analysed by simple and multiple factors Logistic regression,then the interaction between the risk factors of VSD was analysed by Logistic regression,other data were analysed byχ~2 test.
2.Serum samples from 56 isolated VSD patients,85 patients with common pediatric diseases and 23 patients with other congenital heart disease(CHD) were detected by CM10 ProteinChip.Data were analyzed by Biomark Wizard software for searching the proteins that were significantly different between serum of VSD and control. Diagnostic model was established by Biomarker Patterns software.
3.Investigate the parents of casese and controls by phone or visitation and obtain the material whether they have contacted the relevant risk factor or not,then use the logistic regression model to analyze these material and risk factors.
4.Collect 200 women' blood sample to extract whole blood DNA and examine the MTHFR C677T mutations.Compare the pregnant outcome of three groups.
5.Design the investigate questionnaire of NTDs knowledge and investigate the reproductive-aged women which took part in class and which didn't.Then compare the resuls of two groups.Design the investigate questionnaire of the taking folic acid state of pregnant women and choose women randomly to fill them.Collect 560 pregnant women who took folic acid and 600 pregnant women who did not take it, compare their pregnant outcomes.Analysis the results by x~2 analysis and ANOVA.
Results
1.115 CHD cases included 46 cases VSD(40.0%)、14 cases PDA(12.2%)、13 cases F4(11.3%)、6 cases ASD(5.2%)、8 cases other simple CHD(7.0%)、28 cases complicated CHD(24.3%).The results showed the percentage of MTHFR C/C、C/T、T/T genotype were 64.8%、29.6%、5.7%respectively,with C and T allele frequency being 79.6% and 20.4%in the healthy population of Guangxi province,meanwhile,the percentage of CBS T/T、T/C、C/C genotype were 42.6%、47.8%、9.6%respectively,with T and C allele frequency being 66.5%and 33.5%.There were significant differences between maternal MTHFR gene C and T allele frequency(P=0.036,OR=1.595, 95%CI:1.029-2.471).There were significant differences between MTHFR gene C and T allele frequency both mother and father(P=0.032,0R=1.724,95%CI:1.043～2.849) for VSD type.The results revealed that 6 factors were related with the occurrence of CHD in offspring:maternal exposures to pesticides in the early stage of pregnancy、suffering from diseases during pregnancy、catching a cold in the early stage of pregnancy、depressed or nervous condition during pregnancy、maternal MTHFR genotype、maternal CB$ genotype;4 factors were related with the occurrence of VSD in offspring:suffering from diseases during pregnancy、using Chinese medicine in the early stage of pregnancy、depressed or nervous condition during pregnancy、maternal MTHFR genotype.There were some interactions between those risk factors of VSD.
2.12 proteins were significantly different between serum of 25 Zhuang isolated VSD patients and 36 Zhuang patients with common pediatric diseases.Mass to charge ratio(m/z) 6640.784,8570.154,8698.278,2244.582,5321.868,6441.972 and 7973.310 were up-regulated in serum of VSD,and m/z 2213.579,4604.572,2142.465,9198.582 and 2169.264 were down-regulated in serum of VSD.8 proteins were significantly different between serum of 21 Han isolated VSD patients and 33 Han patients with common pediatric diseases,m/z 6442.233,3322.694,6640.853,5122.828,8702.852, 2746.566 and 8574.304 were up-regulated in serum of VSD,and m/z 2823.419 was down-regulated in serum of VSD.21 proteins were significantly different between serum of 56 isolated VSD patients and 85 patients with common pediatric diseases. m/z 6640.784,8571.079,6441.972,8698.804,3322.549,2128.960,2291.255,2055.652, 2243.846 and 2.99.661 were up-regnlated in serum of VSD,and m/z 2050.946, 9306.537,7783.535,9198.666,2143.745,4604.572,7993.109,2824.602,2230.218, 2083.311 and 9360.675 were down-regulated in serum of VSD.25 proteins were significantly different between serum of 56 isolated VSD patients and 23 patients with other CHD.m/z 8571.079,8698.804,6639.783,6441.008,8889.333,9412.899,9360.333, 4793.333 and 9299.101 were up-regulated in serum of VSD,and m/z 3197.867, 2050.759,2040.154,2824.602,4307.323,3483.920,2961.282,2238.446,2022.592, 2010.471,2311.964,4125.468,2781.738,5308.783,5642.844 and 2260.730 were down-regulated in serum of VSD.25 proteins were significantly different among serum of 56 isolated VSD patients,85 patients with common pediatric diseases and 23 patients with other CHD.m/z were 8570.154,6640.784,6441.972,9360.675,8901.488, 3198.355,2917.269,9262.327,9415.030,2824.394,9198.963,9306.537,4604.572, 3319.479,8691.856,4307.360,5322.994,3269.890,4794.334,2747.381,3483.111, 5309.276,7995.957,3381.451 and 5644.239,respectively.
3.In the serum diagnostic model of isolated VSD and patients with common pediatric diseases,the area under receiver operating characteristic curve,accuracy, sensitivity,specificity,positive predictive value and negative predictive value of the intact model were 0.984,96.51%(83/86),97.06%(33/34),96.15%(50/52),94.29% (33/35) and 98.04%(50/51),respectively.The area under receiver operating characteristic curve,accuracy,sensitivity,specificity,positive predictive value and negative predictive value of the terse model were 0.913,88.37%(76/86),97.06% (33/34),82.69%(43/52),78.57%(33/42) and 97.73%(43/44),respectively.In the diagnostic values of these 2 models,except the specificity of the intact model was better than the terse model,others were similar(P＞0.05).(7) In the serum diagnostic model of isolated VSD and patients without VSD,the area under receiver operating characteristic curve,accuracy,sensitivity,specificity,positive predictive value and negative predictive value of the intact model were 0.988,95.00%(95/100),100.00% (34/34),92.42%(61/66),87.18%(34/39) and 100.00%(61/61),respectively.The area under receiver operating characteristic curve,accuracy,sensitivity,specificity, positive predictive value and negative predictive value of the terse model were 0.948, 94.00%(94/100),88.24%(30/34),96.97%(64/66),93.75%(30/32) and 94.12% (64/68),respectively.The diagnostic values of these 2 models were similar(P＞0.05), too.
4.The incidence rate of neural tube defects is 0.987%0.Prevalence in country are higher than in city.The result of logistic regression analysis revealed that mother malnutrition,hyperemesis gravidarum,fever and father alcoholism are factors which positively relative to neural tube defects.
5.The result of mutation of MTHFR C677T is C\C 59.5%,C/T 34.0%,T/T 6.5%.The difference of birth weight and Apgar abnormal rate of three groups have no significant meaning.
6.In the 554 pregnant women,83(15%) women took folic acid everyday from 3 months before pregnancy to 3 months after pregnancy,122(22.2%)women took folic acid after pregnancy,27(4.9%) women took folic acid only when they did not forgot it.The ratio of folic-acid-taking in lower educated subjects level such as only obtain junior middle school and below middle school is the lowest,33.3%and 33.1%;the ratio of the junior college is 48.9%%,the rate of university is 65.0%.
7.The rate of reproductive-aged women who know that folic acid can prevent NTDs is 48%,who know taking folic acid must before pregnancy is only 13.4%,who plan to take folic acid before pregnancy is only 23.0%;who know the types of NTDs is 15.0%,who know the possible reasons of NTDs is 26.2%.After we past these information on some reproductive women,those knowledge rates are significant enhanced and over 78.0%.The rate of reproductive-aged women whose knowledge level is junior middle school and below junior middle school and who realize taking folic acid can reduce NTDs is 14.28%.The rate of planning to take folic acid before pregnancy of these women is 7%,however,the ratio of such two situations of university level women are separately 86.89%,73.91%.
8.The congenital defects rate of group which took folic acid is 8.96%0,the average birth weight of them is 3237.0g,the premature baby ratio is 6.43%0.These three kinds of data of untaking folic acid group is 13.33%o,3119.3g and 8.50%0,respectively.The difference of average birth weight between two groups is significant.
Conclusions
1.Maternal MTHFR gene 677 C→T mutation may be one of the reasons of the occurrence of CHD in offspring,the high level of parents' T allele frequency may be related with the occurrence of VSD in offspring,however,parents' CBS gene 833 T→C mutation does not appear to be involved in offspring's CHD.The risk factors of CHD don't keep the same with VSD type completely.There are interactions between risk factors for the occurrence of VSD,the results suggest that there should be mainly caused by a interaction of two risk factors among all risk factors with the occurrence of other CHD types.
2.The proteins among serum of isolated VSD patients,patients with common pediatric diseases and patients with other CHD are different,m/z 6441,6640,8570 and 8700 are possible to be the serum protein biomarkers of VSD.
3.The 2 terse models,which were constructed by serum protein profiling,have high accuracy,and show great potential for diagnosis of VSD.
4.SELDI-TOF-MS technology is an effective tool for searching the serum protein biomarkers of VSD,and for developing serum diagnosis technology of VSD.
5.In order to reduce the incidence rate of neural tube defects,child-bearing aged women should not only increase the folic acid intake but also avoid to exposure under enviromental risk factors.
6.The mutations of MTHFR C677T varied between places and people.The result of MTHFR C677T mutation in health pregnant-aged women can provide valuable data for following health care of pregnant women.
7.The knowledge regarding of birth defects such as NTDs and using folic acid to prevent it have not been popularized yet among related people.Folic acid has not been widely used.After we spread these knowledge to reproductive-aged women,their knowledge regarding of NTDs and using folic acid to prevent NTDs has been significant improved.
8.We suggest that the government should take action and all government departments work cooperatly in order to spread how to preventing NTDs and the benefit of using folic acid to reproductive-aged women widely.Enhance the women'attention about these useful information.Use several methods such as offering NTDs knowledge course to reproductive-aged women,encouraging them to use folic acid and understanding rate of NTDs,and so on.Our ultimate target is to reduce the birth rate of NTDs and other congenital anomalies,improve mother and baby healthas well as the population health quality.
1、探讨父母亚甲基四氢叶酸还原酶(MTHFR)基因C677T、胱硫醚β-合成酶(CBS)基因T833C、环境因素与子代先天性心脏病(CHD)发生的相关性;了解CHD及室间隔缺损(VSD)类型的危险因素;分析危险因素交互作用对VSD发生的影响。
2、筛选单纯性VSD血清标志蛋白并构建其血清诊断模型,为进一步从蛋白质分子水平研究单纯性VSD的致病机理及发展其血清学诊断方法奠定基础。
3、了解广西神经管畸形(NTDs)的基本分布情况,分析环境及行为危险因素。
4、了解广西健康育龄人群MTHFR基因位点突变的分布及其与妊娠结局的联系。
5、了解育龄妇女对NTDs的认知度、增补叶酸的依从性和评价宣教效果,为预防NTDs寻求更有效的干预模式。
研究方法
1、采用1∶1配对病例对照研究方法,对来自广西的115对CHD患儿与对照儿父母进行访谈式调查并抽取父母静脉血3ml作基因型分析,应用PCR限制性片段长度多态性(PCR-RFLP)方法检测MTHFR基因C677T,PCR扩增阻滞突变体系(PCR-ARMS)方法检测CBS基因T833C。对CHD、VSD可能的危险因素进行Logistic回归分析,对筛选出VSD的危险因素之间作交互作用分析,其他数据分析作x~2检验。
2、用CM10芯片检测56例单纯性VSD、85例儿科常见病患儿及23例其它CHD患儿血清,用Biomark Wizard软件分析数据、筛选VSD血清差异蛋白,用BiomarkerPatterns软件构建诊断模型。
3、以入户或电话采访的方式对NTDs和对照的双亲进行调查,获取他们是否暴露于相关环境危险因素的资料,对暴露因素进行Logistic回归分析。
4、抽取早孕妇女静脉血,提取全血DNA,用PCR-RFLP方法检测MTHFR基因位点多态性,再比较其妊娠结局。
5、对参加NTDs知识学习和未参加学习的新婚育龄妇女按调查表内容展开调查,比较两组调查结果;并收集孕妇服用叶酸情况,追踪其妊娠结局。结果用卡方检验和方差分析进行统计分析。
研究结果
1、115例CHD各类型组成VSD 46例、PDA 14例、F4 13例、ASD 6例、其他单纯类型8例、复杂型CHD 28例。广西健康人群的MTHFR基因C/C、C/T、T/T三种基因型构成比分别为64.8%、29.6%、5.7%,C等位基因频率为79.6%,T等位基因频率为20.4%,CBS基因T/T、T/C、C/C三种基因型构成比分别为42.6%、47.8%、9.6%,T等位基因频率为66.5%,C等位基因频率为33.5%。母亲MTHFR基因的C与T等位基因频率比较差异具有统计学意义(P=0.036,OR=1.595,95%CI:1.029～2.471);对于VSD类型,父母组合的MTHFR基因C与T等位基因频率比较差异具有统计学意义(P=0.032,OR=1.724,95%CI:1.043～2.849)。Logistic回归分析表明,母亲孕早期接触农药、妊娠合并症、孕早期感冒、孕期情绪状况、母MTHFR基因型、母CBS基因型为子代发生CHD的危险因素;妊娠合并症、孕早期服中成药、孕期情绪状况、母MTHFR基因型为子代发生VSD的危险因素。交互作用分析表明妊娠合并症与孕期情绪状况、母MTHFR基因型与妊娠合并症、孕早期服中成药、孕期情绪状况间对VSD的发生存在交互作用。
2、25例壮族单纯性VSD与36例壮族儿科常见病儿血清蛋白质谱比较,有7个蛋白成分在VSD血清中高表达,5个蛋白下调;21例汉族单纯性VSD与33例汉族儿科常见病儿血清蛋白质谱比较,有7个蛋白成分高表达,1个蛋白下调;不分民族56例单纯性VSD与85例儿科常见病儿血清蛋白质谱比较,有10个蛋白成分高表达,11个蛋白下调;不分民族56例单纯性VSD与23例其它CHD血清蛋白质谱比较,有9个蛋白成分高表达,16个蛋白下调;不分民族56例单纯性VSD、85例儿科常见病儿与23例其它CHD血清蛋白质谱比较,有25个蛋白成分在三组之间有统计学差异;
3、在单纯性VSD与儿科常见病的血清诊断模型中,完整模型ROC曲线下面积为0.984,预测准确率为96.51%,灵敏度为97.06%,特异度为96.15%,阳性预测值为94.29%,阴性预测值为98.04%,简化模型分别为0.913、88.37%、97.06%、82.69%、78.57%和97.73%,两模型各主要诊断指标比较,除特异度为完整模型优于简化模型外,其它均无统计学差异;在单纯性VSD与非VSD的血清诊断模型中,完整模型ROC曲线下面积为0.988,预测准确率为95.00%,灵敏度为100.00%,特异度为92.42%,阳性预测值为87.18%,阴性预测值为100.00%,简化模型分别为0.948、94.00%、88.24%、96.97%、93.75%和94.12%,两模型主要诊断指标比较无统计学意义。
4、广西七城市NTDs发生率为9.87/万,无脑儿、脑积水占的比例较高,居住地在农村占的比例比城市略高。母亲营养缺乏、患有妊娠并发症、孕期发烧和父亲饮酒是NTDs发生的危险因素。
5、MTHFR基因多态性检测结果为野生基因型59.5%,杂合突变型34%,纯合突变型6.5%,三组基因型围产儿的出生体重和新生儿评分异常率的差别无统计学意义。
6、554名妊娠妇女中,在孕前和孕后3个月每天服用叶酸的83名,占15.0%,怀孕后开始服用的122名,占22.2%,断续服用的27名,占4.9%,未服用叶酸的322名,占57.9%;文化程度初中和初中以下的妇女服用叶酸率较低,分别为33.3%和33.1%,大专的是48.996,大学及以上是65.096。
7、育龄妇女知道叶酸可以预防NTDs的有48%,知道服用叶酸预防NTDs从孕前开始的只有13.4%,计划服用叶酸的只有23%,知道NTDs类型的有15%,知道NTDs发生的可能原因有26.2%,经过宣传讲解后,对NTDs和叶酸的认知率都提高到78%以上;文化程度为初中及以下的知道叶酸可以预防NTDs的只有14.28%,计划孕前开始服用叶酸的只有7.12%,而大学及以上的分别是86.96%,73.91%。
8、服用叶酸组出生缺陷检出率为8.96‰,平均出生体重为3237.0克,早产儿发生率为6.43‰;未服用叶酸组分别为13.33‰、3119.3克和8.50‰,其中平均出生体重的差别有统计学意义。
研究结论
1、母亲MTHFR基因677TT型与子代CHD发生有关,父母双方MTHFR基因677C→T突变与子代VSD发生有关,父母CBS基因833T→C突变与子代CHD无相关性。母亲孕早期接触农药、妊娠合并症、孕早期感冒、孕期情绪状况、母MTHFR基因型为子代发生CHD的危险因素;妊娠合并症、孕早期服中成药、孕期情绪状况、母MTHFR基因型为子代发生VSD的危险因素。不分型CHD总的危险因素与VSD的危险因素不尽相同,交互作用分析提示危险因素共同引起子代VSD发生的过程中,存在着主要由某两个危险因素交互作用影响的可能,亦提示各类型CHD的发生存在相同的情况。
2、单纯性VSD、儿科常见病儿与其它CHD血清蛋白质存在差异,质荷比6441、6640、8570及8700的蛋白质可能是VSD的血清蛋白标志物。
3、两种VSD血清简化诊断模型具有较高的准确性,有较好的应用前景。
4、表面增强激光解吸/电离飞行时间质谱技术是寻找VSD标志蛋白和发展VSD血清学诊断技术的有效工具。
5、为了减少NTDs的发生,育龄妇女除了增补叶酸以外,还应避免暴露于某些环境危险因素。
6、不同地区、不同人群MTHFR基因分布各有特点,存在明显的群体差异,检测得到广西健康人群的MTHFR基因C677位点突变分布可为今后优生保健的健康筛查工作提供依据。
7、育龄妇女对叶酸和NTDs的知晓率较低,叶酸预防NTDs知识尚未得到很好的普及,叶酸利用率较低,通过健康干预使育龄妇女对NTDs的知晓率和叶酸的利用率均显著提高。
Objective
1.To explore congenital heart diseases(CHD) in offspring in association with parental MTHFR gene C677T and CBS gene T833C;To identify the risk factors of CHD and VSD type with Logistic regression;To explore the interaction among the risk factors of VSD type.
2.Using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry(SELDI-TOF-MS) technology to screen serum protein markers,and to construct serum diagnostic model of isolated ventricular septal defect(VSD).As a pilot study,it aims to lay the foundations for investigating the pathogenesis of VSD at protein molecular level,and for developing serum diagnosis technology of VSD.
3.To investigate the general distribution and environmental risk factors of neural tube defects in Guangxi province.
4.To understand corelationship of health women's mutations of the methylenetetrahydrofolate reductase(MTHFR) gene in Guangxi and the MTHFR C677T mutation and pregnancy outcomes.
5.To assess the knowledge of NTDs of the reproductive-aged women and their compliancy about using folic acid.Spread the knowledge about NTDs to the reproductive-aged women and assess the effects.To make the people attach important to taking folic acid and find a more effective intervention model for NTDs preventing.
Methods
1.To investigate 115 pairs case-control children and their parents who came from Guangxi province with 1:1 case-control study,we investigated possible risk factors by questionnaire,parents' blood samples were collected to examine genotype.We adapted PCR-RFLP method to identify MTHFR gene 677 C→T mutation and PCR-ARMS method was used to identify CBS gene 833 T→C mutation.The possible risk factors were analysed by simple and multiple factors Logistic regression,then the interaction between the risk factors of VSD was analysed by Logistic regression,other data were analysed byχ~2 test.
2.Serum samples from 56 isolated VSD patients,85 patients with common pediatric diseases and 23 patients with other congenital heart disease(CHD) were detected by CM10 ProteinChip.Data were analyzed by Biomark Wizard software for searching the proteins that were significantly different between serum of VSD and control. Diagnostic model was established by Biomarker Patterns software.
3.Investigate the parents of casese and controls by phone or visitation and obtain the material whether they have contacted the relevant risk factor or not,then use the logistic regression model to analyze these material and risk factors.
4.Collect 200 women' blood sample to extract whole blood DNA and examine the MTHFR C677T mutations.Compare the pregnant outcome of three groups.
5.Design the investigate questionnaire of NTDs knowledge and investigate the reproductive-aged women which took part in class and which didn't.Then compare the resuls of two groups.Design the investigate questionnaire of the taking folic acid state of pregnant women and choose women randomly to fill them.Collect 560 pregnant women who took folic acid and 600 pregnant women who did not take it, compare their pregnant outcomes.Analysis the results by x~2 analysis and ANOVA.
Results
1.115 CHD cases included 46 cases VSD(40.0%)、14 cases PDA(12.2%)、13 cases F4(11.3%)、6 cases ASD(5.2%)、8 cases other simple CHD(7.0%)、28 cases complicated CHD(24.3%).The results showed the percentage of MTHFR C/C、C/T、T/T genotype were 64.8%、29.6%、5.7%respectively,with C and T allele frequency being 79.6% and 20.4%in the healthy population of Guangxi province,meanwhile,the percentage of CBS T/T、T/C、C/C genotype were 42.6%、47.8%、9.6%respectively,with T and C allele frequency being 66.5%and 33.5%.There were significant differences between maternal MTHFR gene C and T allele frequency(P=0.036,OR=1.595, 95%CI:1.029-2.471).There were significant differences between MTHFR gene C and T allele frequency both mother and father(P=0.032,0R=1.724,95%CI:1.043～2.849) for VSD type.The results revealed that 6 factors were related with the occurrence of CHD in offspring:maternal exposures to pesticides in the early stage of pregnancy、suffering from diseases during pregnancy、catching a cold in the early stage of pregnancy、depressed or nervous condition during pregnancy、maternal MTHFR genotype、maternal CB$ genotype;4 factors were related with the occurrence of VSD in offspring:suffering from diseases during pregnancy、using Chinese medicine in the early stage of pregnancy、depressed or nervous condition during pregnancy、maternal MTHFR genotype.There were some interactions between those risk factors of VSD.
2.12 proteins were significantly different between serum of 25 Zhuang isolated VSD patients and 36 Zhuang patients with common pediatric diseases.Mass to charge ratio(m/z) 6640.784,8570.154,8698.278,2244.582,5321.868,6441.972 and 7973.310 were up-regulated in serum of VSD,and m/z 2213.579,4604.572,2142.465,9198.582 and 2169.264 were down-regulated in serum of VSD.8 proteins were significantly different between serum of 21 Han isolated VSD patients and 33 Han patients with common pediatric diseases,m/z 6442.233,3322.694,6640.853,5122.828,8702.852, 2746.566 and 8574.304 were up-regulated in serum of VSD,and m/z 2823.419 was down-regulated in serum of VSD.21 proteins were significantly different between serum of 56 isolated VSD patients and 85 patients with common pediatric diseases. m/z 6640.784,8571.079,6441.972,8698.804,3322.549,2128.960,2291.255,2055.652, 2243.846 and 2.99.661 were up-regnlated in serum of VSD,and m/z 2050.946, 9306.537,7783.535,9198.666,2143.745,4604.572,7993.109,2824.602,2230.218, 2083.311 and 9360.675 were down-regulated in serum of VSD.25 proteins were significantly different between serum of 56 isolated VSD patients and 23 patients with other CHD.m/z 8571.079,8698.804,6639.783,6441.008,8889.333,9412.899,9360.333, 4793.333 and 9299.101 were up-regulated in serum of VSD,and m/z 3197.867, 2050.759,2040.154,2824.602,4307.323,3483.920,2961.282,2238.446,2022.592, 2010.471,2311.964,4125.468,2781.738,5308.783,5642.844 and 2260.730 were down-regulated in serum of VSD.25 proteins were significantly different among serum of 56 isolated VSD patients,85 patients with common pediatric diseases and 23 patients with other CHD.m/z were 8570.154,6640.784,6441.972,9360.675,8901.488, 3198.355,2917.269,9262.327,9415.030,2824.394,9198.963,9306.537,4604.572, 3319.479,8691.856,4307.360,5322.994,3269.890,4794.334,2747.381,3483.111, 5309.276,7995.957,3381.451 and 5644.239,respectively.
3.In the serum diagnostic model of isolated VSD and patients with common pediatric diseases,the area under receiver operating characteristic curve,accuracy, sensitivity,specificity,positive predictive value and negative predictive value of the intact model were 0.984,96.51%(83/86),97.06%(33/34),96.15%(50/52),94.29% (33/35) and 98.04%(50/51),respectively.The area under receiver operating characteristic curve,accuracy,sensitivity,specificity,positive predictive value and negative predictive value of the terse model were 0.913,88.37%(76/86),97.06% (33/34),82.69%(43/52),78.57%(33/42) and 97.73%(43/44),respectively.In the diagnostic values of these 2 models,except the specificity of the intact model was better than the terse model,others were similar(P＞0.05).(7) In the serum diagnostic model of isolated VSD and patients without VSD,the area under receiver operating characteristic curve,accuracy,sensitivity,specificity,positive predictive value and negative predictive value of the intact model were 0.988,95.00%(95/100),100.00% (34/34),92.42%(61/66),87.18%(34/39) and 100.00%(61/61),respectively.The area under receiver operating characteristic curve,accuracy,sensitivity,specificity, positive predictive value and negative predictive value of the terse model were 0.948, 94.00%(94/100),88.24%(30/34),96.97%(64/66),93.75%(30/32) and 94.12% (64/68),respectively.The diagnostic values of these 2 models were similar(P＞0.05), too.
4.The incidence rate of neural tube defects is 0.987%0.Prevalence in country are higher than in city.The result of logistic regression analysis revealed that mother malnutrition,hyperemesis gravidarum,fever and father alcoholism are factors which positively relative to neural tube defects.
5.The result of mutation of MTHFR C677T is C\C 59.5%,C/T 34.0%,T/T 6.5%.The difference of birth weight and Apgar abnormal rate of three groups have no significant meaning.
6.In the 554 pregnant women,83(15%) women took folic acid everyday from 3 months before pregnancy to 3 months after pregnancy,122(22.2%)women took folic acid after pregnancy,27(4.9%) women took folic acid only when they did not forgot it.The ratio of folic-acid-taking in lower educated subjects level such as only obtain junior middle school and below middle school is the lowest,33.3%and 33.1%;the ratio of the junior college is 48.9%%,the rate of university is 65.0%.
7.The rate of reproductive-aged women who know that folic acid can prevent NTDs is 48%,who know taking folic acid must before pregnancy is only 13.4%,who plan to take folic acid before pregnancy is only 23.0%;who know the types of NTDs is 15.0%,who know the possible reasons of NTDs is 26.2%.After we past these information on some reproductive women,those knowledge rates are significant enhanced and over 78.0%.The rate of reproductive-aged women whose knowledge level is junior middle school and below junior middle school and who realize taking folic acid can reduce NTDs is 14.28%.The rate of planning to take folic acid before pregnancy of these women is 7%,however,the ratio of such two situations of university level women are separately 86.89%,73.91%.
8.The congenital defects rate of group which took folic acid is 8.96%0,the average birth weight of them is 3237.0g,the premature baby ratio is 6.43%0.These three kinds of data of untaking folic acid group is 13.33%o,3119.3g and 8.50%0,respectively.The difference of average birth weight between two groups is significant.
Conclusions
1.Maternal MTHFR gene 677 C→T mutation may be one of the reasons of the occurrence of CHD in offspring,the high level of parents' T allele frequency may be related with the occurrence of VSD in offspring,however,parents' CBS gene 833 T→C mutation does not appear to be involved in offspring's CHD.The risk factors of CHD don't keep the same with VSD type completely.There are interactions between risk factors for the occurrence of VSD,the results suggest that there should be mainly caused by a interaction of two risk factors among all risk factors with the occurrence of other CHD types.
2.The proteins among serum of isolated VSD patients,patients with common pediatric diseases and patients with other CHD are different,m/z 6441,6640,8570 and 8700 are possible to be the serum protein biomarkers of VSD.
3.The 2 terse models,which were constructed by serum protein profiling,have high accuracy,and show great potential for diagnosis of VSD.
4.SELDI-TOF-MS technology is an effective tool for searching the serum protein biomarkers of VSD,and for developing serum diagnosis technology of VSD.
5.In order to reduce the incidence rate of neural tube defects,child-bearing aged women should not only increase the folic acid intake but also avoid to exposure under enviromental risk factors.
6.The mutations of MTHFR C677T varied between places and people.The result of MTHFR C677T mutation in health pregnant-aged women can provide valuable data for following health care of pregnant women.
7.The knowledge regarding of birth defects such as NTDs and using folic acid to prevent it have not been popularized yet among related people.Folic acid has not been widely used.After we spread these knowledge to reproductive-aged women,their knowledge regarding of NTDs and using folic acid to prevent NTDs has been significant improved.
8.We suggest that the government should take action and all government departments work cooperatly in order to spread how to preventing NTDs and the benefit of using folic acid to reproductive-aged women widely.Enhance the women'attention about these useful information.Use several methods such as offering NTDs knowledge course to reproductive-aged women,encouraging them to use folic acid and understanding rate of NTDs,and so on.Our ultimate target is to reduce the birth rate of NTDs and other congenital anomalies,improve mother and baby healthas well as the population health quality.
引文
[1]罗美瑜.我国出生缺陷的现状及干预.海峡预防医学杂志,2006:12(5):1-2.
[2]黄越华,陈赤,曾萼.2000-2005年广西出生缺陷监测结果分析.应用预防医学,2006:12(6):367-368,344.
[3]朱军,周光萱,代礼,等.1996-2000年全国围产期先天性心脏病发生率的分析.四川大学学报(医学版),2004:35(6):875 877.
[4]仇小强,张志勇,覃益敏,等.广西壮族儿童先天性心脏病危险因素的配对研究.中国公共卫生学报,1999:18(3):132-134.
[5]王晓明,张国成,韩美玉,等.先天性心脏病心脏组织中TORCH病原基因的检测.中华实验和临床病毒学杂志,2001:15(2):176-178.
[6]Scanlon KS,Ferencz C,Loffredo CA,et al.Preconceptional folate intake and malformations of the cardiac outflow tract.Epidemiology,1998;9(1):95-98.
[7]杨江帆,许月珍,李萍,等.嘉兴市20436例新生儿先天性心脏病流行病学调查.中华儿科杂志,1997:35(8):417.
[8]Goyette P,Sumner JS,Milos R,et al.Human methylenetetrahydrofolate reductase:isolation of cDNA,mapping and mutation identification.Nat Genet,1994;7(2):195-200.
[9]刘虹,李松,叶鸿瑁,等.血浆同型半胱氨酸、叶酸、5,10-亚甲基四氢叶酸还原酶基因多态性与先天性心脏病的相关性研究.中华围产医学杂志,2002:5(2):102-105.
[10]Wenstrom KD,Johanning GL,Johnston KE,et al.Association of the C677T methylenetetrahydrofolate reductase mutation and elevated homocysteine levels with congenital cardiac malformations.Am J Obstet Gynecol,2001;184(5):806-812.
[11]Junker R,Kotthoff S,Vielhaber H,et al.Infant methylenetetrahydrofolate reductase 677TT genotype is a risk factor for congenital heart disease.Cardiovasc Res,2001;51(2):251-254.
[12]杨德业,张怀勤,黄伟剑,等.室间隔缺损新的相关基因-蛋白酪氨酸激酶的实验研究.中国病理生理杂志,2004:20(1):117-119.
[13]李勇,陈祥贵.应用基因芯片技术探讨小鼠胚胎心脏发育过程中的差异表达基因.疾病控制杂志,2003:7(4):291-296.
[14]R(o|¨)cken C,Ebert MPA,Roessner A.Proteomics in pathology,research and practice.Pathology,Research and Practice,2004:200(2):69-82.
[15]肖雪嫒,卫秀平,何大澄.应用蛋白质芯片技术从血清中筛选肺癌标志蛋白.中国科学(C辑),2003;33(4):323-328.
[16]Poon TC,Hui AY,Chan HL,et al.Prediction of liver fibrosis and cirrhosis in chronic hepatitis B infection by serum proteomic fingerprinting:a pilot study.Clinical Chemistry,2005:51(2):328-335.
[17]Torf CP,Katz EA,Bateson TF,et al.Maternal medications and environmental exposures as risk factors for gastroschisis.Teratology,1996:54(2):84-92.
[18]代礼,朱军.1996-2000年全国神经管畸形的动态监测.中华预防医学杂志,2002:36(6).402-404.
[19]Williamson R.Prevention of birth defects:folic acid,Biol Res Nurs,2001;3(1):33-38.
[20]李竹,陈新,赵平,等.妇女增补叶酸预防神经管畸形推广研究五年成果和工作总结.中国公共卫生,2001:17(8):725-727.
[1]Hoffman JI, Kaplan S. The incidence of congenital heart disease. J Am Coll Cardiol 2002;39(12):1890-900.
[2]Eugene Braunwald[主编],陈灏珠[主译].心脏病学.第5版,北京:人民卫生出版社,1999:809.
[3]Green EK, Priestley MD, Waters J, et al. Detailed mapping of a congenital heart disease gene in chromosome 3p25. J Med Genet 2000;37(8):581-7.
[4]Chung MY, Lu JH, Chien HP, et al. Chromosome 22qll microdeletion in conotruncal heart defects: clinical presentation, parental origin and de novo mutations. Int J Mol Med 2001;7(5):501-5.
[5]Shi YR, Hsieh KS, Wu JY, et al. Molecular analysis of syndromic congenital heart disease using short tandem repeat markers and semiquantitative polymerase chain reaction method. Pediatr Int 2002;44(3):264-8.
[6]Digilio MC, Marino B, CapolinoR, et al. Familial recurrence of nonsyndromic congenital heart defects in first degree relatives of patients with deletion 22q11.2. Am J Med Genet A 2005 Jan 24; [Epub ahead of print]
[7]Li D, Ahmad F, Gardner MJ, et al. The locus of a novel gene responsible for arrhythmogenic right-ventricular dysplasia characterized by early onset and high penetrance maps to chromosome 10pl2-pl4. Am J Hum Genet 2000;66(1):148-56.
[8]Digilio MC, Marino B, Giannotti A, et al. Heterotaxy with left atrial isomerism in a patient with deletion 18p. Am J Med Genet 2000;94(3):198-200.
[9]GiglioS, Graw SL, Gimelli G, et al. Deletion of a 5-cM region at chromosome 8p23 is associated with a spectrum of congenital heart defects. Circulation 2000;102(4):432-7.
[10]Zhu W, Shiojima I, Hiroi Y, et al. Functional analyses of three Csx/Nkx-2. 5 mutations that cause human congenital heart disease. J Biol Chem 2000;275(45):35291-6.
[11]Vaughan CJ,Basson CT.Molecular determinants of atrial and ventricular septal defects and patent ductus arteriosus.Am J Med Genet 2000;97(4):304-9.
[12]Goldmuntz E,Geiger E,Benson DW.NKX2.5 mutations in patients with tetralogy of fallot.Circulation 2001;104(21):2565-8.
[13]Reamon-Buettner SM,Borlak J.Somatic NKX2-5 mutations as a novel mechanism of disease in complex congenital heart disease.J Med Genet 2004;41(9):684-90.
[14]孙淼,邱广蓉,孙桂凤,等.人类单纯性先天性心脏病患者Nkx 2-5基因突变及表达的研究.中国医科大学学报2001:30(5):321-24.
[15]Lee Y,Song AJ,Baker R,et al.Jumonji,a nuclear protein that is necessary for normal heart development.Circ Res 2000;86(9):932-8
[16]Goldmuntz E,Bamford R,Karkera JD,et al.CFC1 mutations in patients with transposition of the great arteries and double-outlet right ventricle.Am J Hum Genet 2002;70(3):776-80.
[17]Eldadah ZA,Hamosh A,Biery NJ,et al.Familial Tetralogy of Fallot caused by mutation in the jaggedl gene.Hum Mol Genet 2001;10(2):163-9.
[18]McFadden DH,Charite J,Richardson JA,et al.A GATA-dependent right ventricular enhancer controls dHAND transcription in the developing heart.Development 2000;127(24):5331-41.
[19]Svensson EC,Huggins GS,Lin H,et al.A syndrome of tricuspid atresia in mice with a targeted mutation of the gene encoding Fog-2.Nat Genet 2000;25(3):353-6.
[20]Ware SM,Peng J,Zhu L,et al.Identification and functional analysis of ZIC3 mutations in heterotaxy and related congenital heart defects.Am J Hum Genet 2004;74(1):93-105.
[21]仇小强,覃益敏,谢晓宇,等.1286例先天性心脏病患儿致病因素的调查研究.同济医科大学学报1999:28(5):399-401.
[22]Carmichael SL,Shaw GM.Maternal life event stress and congenital anomalies.Epidemiology 2000;11(1):30-5.
[23]Loffredo CA,Silbergeld EK,Ferencz C,et al.Association of transposition of the great arteries in infants with maternal exposures to herbicides and rodenticides.Am J Epidemiol 2001;153(6):529-36.
[24]Botto LD,Loffredo C,Scanlon KS,et al.Vitamin A and cardiac outflow tract defects.Epidemiology 2001;12(5):491-6.
[25]Sze RW,Yutzey KE.The molecular genetic revolution in congenital heart disease.AJR Am J Roentgenol 2001;176(3):575-81.
[26]Scanlon KS,Ferencz C,Loffredo CA,et al.Preconceptional folate intake and malformations of the cardiac outflow tract.Epidemiology 1998:9(1):95-8.
[27]杨江帆,许月珍,李萍,等.妊娠初期增补叶酸预防新生儿先天性心脏病作用的观察.中华儿科杂志1998:36(8):488.
[28]Goyette P,Sumner JS,Milos R,et al.Human methylenetetrahydrofolate reductase:isolation of cDNA,mapping and mutation identification.Nat Genet 1994;7(2):195-200.
[29]Frosst P,Blom HJ,Milos R,et al.A candidate genetic risk factor for vascular disease:a common mutation in methylenetetrahydrofolate reductase.Nat Genet 1995;10(1):111-3.
[30]李勇,李松,陈光慧,等.HCY-2基因和同型半胱氨酸与鸡胚先天性心脏畸形发生的关系.中华医学杂志2000:80(2):131-34.
[31]Rosenquist TH,Ratashak SA,Selhub J.Homocysteine induces congenital defects of the heart and neural tube:effect of folic acid.Proc Natl Acad Sci USA 1996;93(26):15227-32.
[32]李秀昌,胡燕燕.同型半胱氨酸代谢异常的分子发病学机制研究进展.国外医学遗传学分册2000:23(5):261-63.
[33]Tsai MY,Garg U,Key NS,et al.Molecular and biochemical approaches in the identification of heterozygotes for homocystinuria.Atherosclerosis 1996:122(1):69-77.
[34]王培林[主编].遗传病学.北京:人民卫生出版社2000:734-50.
[35]Chien KR.Genomic circuits and the integrative biology of cardiac diseases.Nature 2000;407(6801):227-32.
[36]刘虹,李松,叶鸿瑁,等.血浆同型半胱氨酸、叶酸、5,10-亚甲基四氢叶酸还原酶基因多态性与先天性心脏病的相关性研究.中华围产医学杂志2002:5(2):102-04.
[37]Wenstrom KD,Johanning GL,Johnston KE,et al.Association of the C677T methylenetetrahydrofolate reductase mutation and elevated homocysteine levels with congenital cardiac malformations.Am J Obstet Gynecol 2001;184(5):806-12;discussion 812-7.
[38]Guitti JC.Epidemiological characteristics of congenital heart diseases in Londrina,Parana south Brazil.Arq Bras Cardiol 2000;74(5):395-404.
[39]Arbour L,Gilpin C,Millor-Roy V,et al.Heart defects and other malformations in the Inuit in Canada:a baseline study.Int J Circumpolar Health 2004;63(3):251-66.
[40]刘薇延,宁寿葆,华邦杰,等.上海市杨浦、徐汇区小儿先天性心脏病发病率及其特点.中华儿科杂志1995;33(6):347-49.
[41]杨江帆,许月珍,李萍,等.嘉兴市20436例新生儿先天性心脏病流行病学调查.中华儿科杂志1997:35(8):416-19.
[42]Jacobs EG,Leung MP,Karlberg J.Birthweight distribution in southern Chinese infants with symptomatic congenital heart disease.J Paediatr Child Health 2003;39(3):191-6.
[43]Kecskes Z,Cartwright DW.Poor outcome of very low birthweight babies with serious congenital heart disease.Arch Dis Child Fetal Neonatal Ed 2002:87(1):F31-3.
[44]Goyette P,Pal A,Milos R,et al.Gene structure of human and mouse methylenetetrahydrofolate reductase(MTHFR).Mamm Genome 1998:9(8):652-6.
[45]Mukherjee M,Joshi S,Bagadi S,et al.A low prevalence of the C677T mutation in the methylenetetrahydrofolate reductase gene in Asian Indians.Clin Genet 2002:61(2):155-9.
[46]Kang SS,Wong PW,Susmano A,et al.Thermolabile methylenetetrahydrofolate reductase:an inherited risk factor for coronary artery disease.Am J Hum Genet 1991:48(3):536-45.
[47]De Franchis R,Mancini FP,D'Angelo A,et al.Elevated total plasma homocysteine and 677C-->T mutation of the 5,10-methylenetetrahydrofolate reductase gene in thrombotic vascular disease.Am J Hum Genet 1996:59(1):262-4.
[48]Motulsky AG.Nutritional ecogenetics:homocysteine-related arteriosclerotic vascular disease,neural tube defects,and folic acid.Am J Hum Genet 1996:58(1):17-20.
[49]朱慧萍,赵如冰,刀京晶,等.中国北方少数民族人群同型半胱氨酸代谢酶的遗传多态性.中国优生优育2000:11(2):51-53.
[50]于佳梅,王新春,陈白滨,等.中国5个民族亚甲基四氢叶酸还原酶基因多态性的研究.人类学学报1998:17(3):242-45.
[51]Kraus JP,Oliveriusova J,Sokolova J,et al.The human cystathionine beta-synthase(CBS) gene:complete sequence,alternative splicing,and polymorphisms.Genomics 1998;52(3):312-24.
[52]Sokolova J,Janosikova B,Terwilliger JD,et al.Cystathionine beta-synthase deficiency in Central Europe:discrepancy between biochemical and molecular genetic screening for homocystinuric alleles.Hum Mutat 2001;18(6):548-9.
[53]Kumar KS,Govindaiah V,Naushad SE,et al.Plasma homocysteine levels correlated to interactions between folate status and methylene tetrahydrofolate reductase gene mutation in women with unexplained recurrent pregnancy loss.J Obstet Gynaecol 2003;23(1):55-8.
[54]Tanis BC,Blom HJ,Bloemenkamp DG,et al.Folate,homocysteine levels,methylenetetrahydrofolate reductase(MTHFR) 677C --> T variant,and the risk of myocardial infarction in young women:effect of female hormones on homocysteine levels.J Thromb Haemost 2004;2(1):35-41.
[55]Botto LD,Yang Q.5,10-Methylenetetrahydrofolate reductase gene variants and congenital anomalies:a HuGE review.Am J Epidemiol 2000;151(9):862-77
[56]Junker R,Kotthoff S,Vielhaber H,et al.Infant methylenetetrahydrofolate reductase 677TT genotype is a risk factor for congenital heart disease.Cardiovasc Res 2001;51(2):251-4.
[57]闫丽盈,李书琴,赵汉杰,等.父母MTHFR基因型与子代先天性心脏病的关系.疾病控制杂志2003:7(2):94-97.
[58]Li Y,Cheng J,Zhu WL,et al.Study of serum Hcy and polymorphisms of Hcy metabolic enzymes in 192 families affected by congenital heart disease.Beijing Da Xue Xue Bao 2005;37(1):75-80.
[59]Ueland PM,Refsum H,Stabler SP,et al.Total homocysteine in plasma or serum:methods and clinical applications.Clin Chem 1993;39(9):1764-79.
[60]赵如冰,李勇,陈星.同型半胱氨酸对体外培养大鼠胚胎生长发育的影响.卫生研究2001:30(1):34-36.
[61]James SJ,Pogribna M,Pogribny IP,et al.Abnormal folate metabolism and mutation in the methylenetetrahydrofolate reductase gene may be maternal risk factors for Down syndrome.Am J Clin Nutr 1999;70(4):495-501.
[62]Nygard O,Vollset SE,Refsum H,et al.Total homocysteine and cardiovascular disease.J Intern Med 1999;246(5):425-54.
[63]Alluri RV,Mohan V,Komandur S,et al.MTHFR C677T gene mutation as a risk factor for arterial stroke:a hospital based study.Eur J Neurol 2005;12(1):40-4.
[64]Brouwer IA,van Dusseldorp M,Thomas CM,et al.Low-dose folic acid supplementation decreases plasma homocysteine concentrations:a randomized trial.Am J Clin Nutr 1999;69(1):99-104.
[65]Jacques PF,Selhub J,Bostom AG,et al.The effect of folic acid fortification on plasma folate and total homocysteine concentrations.N Engl J Med 1999;340(19):1449-54.
[66]Bronstrup A,Hages M,Prinz-Langenohl R,et al.Effects of folic acid and combinations of folic acid and vitamin B-12 on plasma homocysteine concentrations in healthy,young women.Am J Clin Nutr 1998;68(5):1104-10.
[67]Botto LD,Mulinare J,Erickson JD.Occurrence of congenital heart defects in relation to maternal mulitivitamin use.Am J Epidemiol 2000;151(9):878-84.
[68]张泽峰,李竹,季成叶,等.孕早期精神受刺激对出生儿单纯性先心病发病的影响.中国公共卫生1999:15(4):307-08.
[69]Kim WG,Suh JW,Chi JG.Nitrofen-induced congenital malformations of the heart and great vessels in rats:an animal model.J Pediatr Surg 1999;34(12):1782-6.
[70]刘毓谷[主编].卫生毒理学基础.第2版 北京:人民卫生出版社1994:150.
[71]Wang X,Zhang G,Liu F,et al.Prevalence of human parvovirus B19 DNA in cardiac tissues of patients with congenital heart diseases indicated by nested PCR and in situ hybridization.J Clin Virol 2004;31(1):20-4.
[72]Bittencourt AL,Garcia AG.Pathogenesis and pathology of hematogenous infections of the fetus and newborn.Pediatr Pathol Mol Med 2002;21(4):353-99.
[73]仇小强,彭如宽,谢晓宇,等.儿童先天性心脏病各分型致病因素的多因多果研究.广西医科大学学报1999:16(4):415-17.
[74]Gittenberger-de Groot AC,Bartelings MM,Deruiter MC,et al.Basics of Cardiac Development for the Understanding of Congenital Heart Malformations.Pediatr Res 2005;57(2):169-76.
[1]Murray JC, Buetow KH, Weber JL, et al. A comprehensive human map with centimorgan density. Science, 1994; 265(5181):2049-2054.
[2]Hudson TJ, Stein LD, Gerety SS, et al. An STS based map of the human genome.Science, 1995; 270(5244):1945-1954.
[3]Lander ES, Linton LM, Birren B, et al. Initial sequencing and analysis of the human genome. Nature, 2001; 409(6822):860-921.
[4]Venter JC, Adams MD, Myers EW, et al. The sequence of the human genome.Science, 2001; 291(5507):1304-1351.
[5]Anderson L, Seilhamer J. A comparison of selected mRNA and protein abundances in human liver. Electrophoresis, 1997; 18(3-4):533-537.
[6]Anderson NL, Anderson NG. Proteome and proteomics: new technologies, new concepts, and new words. Electrophoresis, 1998; 19(11):1853-1861.
[7]Chen G, Gharib TG, Huang CC, et al. Discordant protein and mRNA expression in lung adenocarcinomas. Mol. Cell Proteomics, 2002; 1(4):304-313.
[8]Rubin MA. Understanding disease cell by cell. Science, 2002; 296(5571):1329-1330.
[9]Ball HJ and Hunt NH. Needle in a haystack: microdissecting the proteome of a tissue. Amino Acids, 2004; 27(1):1-7.
[10]Melle C, Ernst G, Schimmel B, et al. A technical triade for proteomic identification and characterization of cancer biomarkers. Cancer Research,2004; 64(12):4099-4104.
[11]Hudelist G, Singer CF, Kubista E, et al. Use of high-throughput arrays for profiling differentially expressed proteins in normal and malignant tissues. Anti-Cancer Drugs,2005; 16(7):683-689.
[12]Service RF. PROTEOMICS:high-speed biologists search for gold in proteins.Science, 2001; 294(5549):2074-2077.
[13]Seibert V,Wiesner A,Buschmann T,et al.Surface-enhanced laser desorption ionization time-of-flight mass spectrometry(SELDI TOF-MS) and ProteinChip~(?) technology in proteomics research.Pathology,Research and Practice,2004:200(2):83-94.
[14]Rosenblatt KP,Bryant-Greenwood P,Killian JK,et al.Serum proteomics in cancer diagnosis and management.Annual Review of Medicine,2004:55(1):97-112.
[15]修瑞娟。微血管医学与蛋白质组学。中国微循环,2004;8(2):69-71.
[16]Wiesner A.Detection of Tumor Markers with ProteinChip~(?) Technology.Current Pharmaceutical Biotechnology,2004;5(1):45-67.
[17]Yasui Y,Pepe M,Thompson ML,et al.A data-analytic strategy for protein biomarker discovery:profiling of high-dimensional proteomic data for cancer detection.Biostatistics,2003:4(3):449-463.
[18]Boguski MS,Mclntosh MW.Biomedical informatics for proteomics.Nature,2003;422(6928):233-237.
[19]Rocken C,Ebert MPA,Roessner A.Proteomics in pathology,research and practice.Pathology,Research and Practice,2004;200(2):69-82.
[20]Wasinger VC,Cordwell SJ,Cerpa-Poljak C,et al Progress with gene-product mapping of the Mollicutes:Mycopiasma genitalium Electrophoresis,1995;16(7):1090-1094.
[21]Peng J,Gygi SP.Proteomics:The move to mixtures.J Mass Spectrom,2001;36(10):1083 - 1091.
[22]Takahashi N,Kaji H,Yanagida M,et al.Proteomics:Advanced technology for the analysis of cellular functionl,2.The Journal of Nutrition,2003;133(6S-I):2090-2096.
[23]Pardanani A,Wieben ED,Spelsberg TC,et al.Primer on medical genomics part Ⅳ:Expression proteomics.Mayo Clinic Proceedings,2002;77(11): 1185-1196.
[24]Zhu H,Bilgin M,Bangham R,et al.Global analysis of protein activities using proteome chips.Science,2001;293(5537):2101-2105.
[25]Amacher DE,Adler R,Herath A,et al.Use of Proteomic Methods to Identify Serum Biomarkers Associated with Rat Liver Toxicity or Hypertrophy.Clinical Chemistry,2005;51(10):1796-1803.
[26]Reymond MA,Steinert R,Kahne T,et al.Expression and functional proteomics studies in colorectal cancer.Pathology,Research and Practice,2004;200(2):119-127.
[27]Hanash S.Disease proteomics.Nature,2003;422(6928):226-232.
[28]Smith DL,Evans CA,Pierce A,et al.Changes in the proteome associated with the action of berabl tyrosine kinase are not related to translational regulation.Mol Cell Proteomics,2002;1(11):876-884.
[29]蔡春,蔡康荣,徐美奕.肝靶向药物载体半乳糖基蛋白的合成及其特性研究。广东医学院学报,2005:23(3):235-237.
[30]Service RF.Gene and protein patents get ready to go head to head.Science,2001;294(5549):2082-2083.
[31]Cho A and Normile D.Nobel Prize in Chemistry.Mastering macromolecules.Science,2002;298(5593):527-528.
[32]Hutchens TW,Yip TY.New desorption strategies for the mass spectrometric analysis of macromolecules.Rapid Commun Mass Spectrom,1993;7(1):576-580.
[33]Tang N,Tornatore P,Weinberger SR.Current developments in SELDI affinity technology.Mass Spectrom Rev,2004;23(1):34-44.
[34]张建中,郑燕华,冯凯,等.SELDI蛋白指纹技术在肿瘤早期诊断中的应用.世界华人消化杂志,2004:12(12):2773-2777.
[35]Issaq HJ,Ueenstra TD,Conrads TP,et al.The SELDI-TOF MS approach to proteomics:protein profiling and biomarker identification.Biochem Biophys Res Commun, 2002; 292(3):587-592.
[36]Grizzlea WE, Adamb BL, Bigbee WL, et al. Serum protein expression profiling for cancer detection: Validation of a SELDI-based approach for prostate cancer. Disease Markers, 2004; 19(4/5):185-195.
[37]Solassol J, Boulle N, Maudelonde T, et al. Clinical proteomics: towards early detection of cancers. Med Sci (Paris). 2005;21(8-9):722-729.
[38]Seibert V, Ebert M and Buschmann T. Advances in clinical cancer proteomics:SELDI-ToF-mass spectrometry and biomarker discovery. Briefings in Functional Genomics and Proteomics, 2005; 4(1):16-26.
[39]von Eggeling F, Junker K, Fiedle W, Wollscheid V, Durst M, Claussen UE.Mass spectrometry meets chip technology: a new proteomic tool in cancer research? Electrophoresis 2001; 22(14):2898-2902 .
[40]Karsan A, Eigl BJ, Flibotte S, Gelmon K, et al. Analytical and preanalytical biases in serum proteomic pattern analysis for breast cancer diagnosis. Clinical Chemistry, 2005; 51(8):1525-1528.
[41]Check E. Proteomics and cancer: running before we can walk? Nature 2004;429(6991):496-497.
[42]Garber K. Debate rages over proteomic patterns. Journal of the National Cancer Institute, 2004;96(11):816-818.
[43]Diamandis EP. Analysis of Serum Proteomic Patterns for Early Cancer Diagnosis:Drawing Attention to potential problems. Journal of the National Cancer Institute, 2004; 96 (5):353-357.
[44]Baggerly KA, Morris JS, Edmonson SR, et al. Signal in noise: evaluating reported reproducibility of serum proteomic tests for ovarian cancer.Journal of the National Cancer Institute, 2005; 97(4):307-309.
[45]Malyarenko DI, Cooke WE, Adam BL, et al. Enhancement of Sensitivity and Resolution of Surface-Enhanced Laser Desorption/Ionization Time-of-Flight Mass Spectrometric Records for Serum Peptides Using Time-Series Analysis Techniques.Clinical Chemistry,2005;51(1):65-74.
[46]孙太欣,彭国光.蛋白质芯片在神经系统疾病进展评估和发病机制研究中的应用与作用.中国临床康复,2005:9(21):178-180.
[47]Rai AJ,Gelfand CA,Haywood BC,et al.HUPO Plasma Proteome Project specimen collection and handling:towards the standardization of parameters for plasma proteome samples.Proteomics,2005;5(13):3262-3277.
[48]Hoffman JI,Kaplan S.The incidence of congenital heart disease.J Am Coll Cardiol,2002;39(12):1890-1900.
[49]王惠珊,袁雪,闫淑娟,等.北京市1992-2000年婴儿及胎婴儿死亡率的监测与干预研究.中华医学杂志,2001;81(23):1424-1426.
[50]朱军,周光萱,代礼,等.1996-2000年全国围产儿先天性心脏病发生率的分析.四川大学学报(医学版),2004:36(6):875-877.
[51]蒋立虹,段昌群,马志强.先天性心脏病流行病学调查研究动态.华西医学,2004:19(3):510-511.107
[52]仇小强,张志勇,覃益敏,等.广西壮族儿童先天性心脏病危险因素的配对研究[J].中国公共卫生学报,1999;18(3):132-134.
[53]仇小强,覃益敏,谢晓宇,等.1286例先天性心脏病患儿致病因素的调查研究[J].同济医科大学学报,1999:28(5):399-401.
[54]Gilboa SM,Mendola P,Olshan AF,et al.Relation between Ambient Air Quality and Selected Birth Defects,Seven County Study,Texas,1997-2000.American Journal of Epidemiology,2005;162(3):238-252.
[55]Ritz B,Yu F,Fruin S,et al.Ambient Air Pollution and Risk of Birth Defects in Southern California.American Journal of Epidemiology,2002;155(1):17-25.
[56]Bateman DN,MaElhatton PR,Dickinson D,et al.A case control study to examine the pharmacological factors underlying ventricular septal defects in the North of England.European Journal of Clinical Pharmacology,2004;60(9):635-641.
[57]Hwang BF,Magnus P,Jaakkola JJK.Risk of Specific Birth Defects in Relation to Chlorination and the Amount of Natural Organic Matter in the Water Supply.American Journal of Epidemiology,2005;156(4):374-382.
[58]Bassili1 A,Mokhtar SA,Dabous NI,et al.Risk factors for congenital heart diseases in Alexandria,Egypt.European Journal of Epidemiology,2000;16(9):805-814.
[59]程光存,严中亚,吴一军,等.儿童先天性心脏病室间隔缺损致病因素分析.心肺血管病杂志,2004:23(4):208-210.
[60]Schott JJ,Beson D W,Basson CT,et al.Congenital heart disease caused by mutation in the transcription factor Nkx 2-5.Science,1998;281(5373):108-111.
[61]宫立国,邱广蓉,邱广斌,等.人类单纯性先天性心脏病中TBX5基因的突变及表达研究.遗传,2003:25(5):533-537.
[62]杨德业,张怀勤,黄伟剑,等.室间隔缺损新的相关基因-蛋白酪氨酸激酶的实验研究.中国病理生理杂志,2004:20(1):117-119.
[63]Kwon YT,Kashina AS,Davydov IV,et al.An essential role of N-terminal arginylation in cardiovascular development.Science,2002;297(5578):96-99.
[64]邱广蓉,孙桂凤,孙森,等.Hox基因与人类室间隔缺损相关性的研究.中华医学杂志,2001:81(3):174-175.
[65]邓伟国,付艳,谢铁男,等.小鼠叉头框C2基因变异致室间隔缺损.吉林大学学报(医学版),2004:30(1):6-9.
[66]李勇,陈祥贵.应用基因芯片技术探讨小鼠胚胎心脏发育过程中的差异表达基因.疾病控制杂志,2003:7(4):291-296.
[67]Brand M,kempf H,paul M,et al.Expression of endothelins in human cardiogenesis. Journal of Molecular Medicine, 2002; 80(11):715-723.
[68]Feng Q, Song W, Lu X, et al. Development of heart failure and congenital septal defects in mice lacking endothelial nitric oxide synthase.Circulation, 2002; 106(7):873-839.
[69]LeeY, Song AJ, Baker R, et al. Jumonji, a nuclear protein that is necessary for normal heart development. Circulation Research, 2000; 86(9): 932-938.
[70]Jung J, Kim TG, Lyons GE, et al. Jumonji Regulates Cardiomyocyte Proliferation via Interaction with Retinoblastoma Protein. J Biol Chem,2005; 280(35): 30916-30923.
[71]LiangX, Zhou Q, Li X, et al. PINCH1 Plays an Essential Role in Early Murine Embryonic Development but Is Dispensable in Ventricular Cardiomyocytes.Mol Cell Biol, 2005; 25(8):3056-3062.
[72]Law YM, Keller BB, Feingold BM, et al. Usefulness of plasma B-type natriuretic peptide to identify ventricular dysfunction in pediatric and adult patients with congenital heart disease. Am J Cardiol, 2005; 95(4):474-478.
[73]Chen H, Shi S, Acosta L, et al. BMP10 is essential for maintaining cardiac growth during murine cardiogenesis. Development, 2004; 131(9):2219-2231.
[74]Zhou HM, Weskamp G, Chesneau V, et al. Essential role for ADAM19 in cardiovascular morphogenesis. Mol Cell Biol, 2004;24(1):96-104.
[75]陈树宝主编.先天性心脏病影像诊断学[M].北京:人民卫生出版社, 2004: 237-244.
[76]Kang X, Xu Y, Wu X, et al. Proteomic Fingerprints for Potential Application to Early Diagnosis of Severe Acute Respiratory Syndrome[J]. Clinical Chemistry, 2005; 51(1):56-64.
[77]Li J, Zhang Z, Rosenzweig J, et al. Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer.Clinical Chemistry, 2002;48(8):1296-1304.
[78]Callen NA,Blackemore KJ,Kan JS.Counseling in congenital heart defects.Obstet Gynecol Surv,1991;46(10):651-655.
[79]Schrader M and Schulz-Knappe P.Peptidomics technologies for human body fluids.Trends Biotechnol.2001;19(10 Supp1):S55-S60.
[80]Liotta LA,Ferrari M,Petricoin EF.Written in blood.Nature,2003;425(6961):905.
[81]Thadikkaran L,Siegenthaler MA,Crettaz D,et al.Recent advances in blood-related proteomics.Proteomics,2005;5(12):3019-3034.
[82]Patterson SD.Proteomics:evolution of the technology.Biotechniques,2003;35(3):440-444.
[83]Zhu H,Snyder M.Protein chip technology.Curr Opin Chem Biol,2003;7(1):55-63.
[84]Aebersold R and Mann M.Mass spectrometry-based proteomics.Nature,2003;422(6928):198-207.
[85]Adkins JN,Varnum SM,Auberry KJ,et al.Toward a human blood serum proteome:analysis by multidimensional separation coupled with mass spectrometry.Mol Cell Proteomics.2002;1(25):947-955.
[86]Zolg JW,Langen H.How industry is approaching.the search for new diagnostic markers and biomarkers.Mol Cell Proteomics,2004;3(4):345-354.
[87]Kas K.On the technicalities of discovering and applying protein biomarkers for cancer prevention.European Journal of Cancer Prevention,2004;13(5):437-446.
[88]邓军,孔祥清,杨荣,等.室间隔缺损介入治疗前后可溶性细胞间黏附分子-1、P选择素、肌钙蛋白Ⅰ的变化及意义.南京医科大学学报(自然科学版),2005:25(8):555-557.
[89]Hortin GL.Can Mass Spectrometric Protein Profiling Meet Desired Standards of Clinical Laboratory Practice? Clin. Chem. 2005; 51(1):3-5.
[90]Banks RE, Stanley AJ, Cairns DA, et al. Influences of Blood Sample Processing on Low-Molecular-Weight Proteome Identified by Surface-Enhanced Laser Desorption/Ionization Mass Spectrometry. Clin Chem,2005; 51(9):1637 - 1649.
[91]Schwegler EE, Cazares L, Steel LF, et al. SELDI-TOF MS Profiling of Serum for Detection of the Progression of Chronic Hepatitis C to Hepatocellular Carcinoma. Hepatology, 2005; 41(3):634-642.
[92]Semmes OJ, Feng Z, Adam BL, et al. Evaluation of Serum Protein Profiling by Surface-Enhanced Laser Desorption/Ionization Time-of-Flight Mass Spectrometry for the Detection of Prostate Cancer: I. Assessment of Platform Reproducibility.Clinical Chemistry, 2005;51(1):102-112.
[93]Kiga C, Nakagawa T, Koizumi K, et al. Expression Patterns of Plasma Proteins in Spontaneously Diabetic Rats after Oral Administration of a Kampo Medicine, Hachimi-jio-gan, Using SELDI ProteinChip Platform. Biological & Pharmaceutical Bulletin, 2005;28(6):1031-1037.
[94]Papadopoulos MC, Abel PM, Agranoff D, et al. A novel and accurate diagnostic test for human African trypanosomiasis [J]. Lancet, 2004; 363(9418):1358-1363.
[95]Tomohiko H, Kazufumi H, Masaya O, et al. Identification of 2 serum biomarkers of renal cell carcinoma by surface enhanced laser desorption/ionization mass spectrometry. The Journal of Urology,2005;174(4, part 1 of 2): 1213-1217.
[1]朱军,周光萱,代礼,等.1996-2000年全国围产儿先天性心脏病发生率的分析.四川大学学报(医学版),2004:36(6):875-877.
[2]Pradat P,Francannet C,Harris JA,et al.The Epidemiology of Cardiovascular Defects,Part Ⅰ:A Study Based on Data from Three Large Registries of Congenital Malformations.Pediatric Cardiology,2003;24(3):195-221.
[3]蒋立虹,段昌群,马志强.先天性心脏病流行病学调查研究动态.华西医学,2004:19(3):510-511.
[4]惠玲.小儿先天性心脏病学[M].北京:北京出版社,1998:710.
[5]杨思源.小儿心脏学[M].北京:人民卫生出版社,2005:125.
[6]仇小强,覃益敏,谢晓宇,等.1286例先天性心脏病患儿致病因素的调查研究.同济医科大学学报,1999:28(5):399-401.
[7]王惠玲.小儿先天性心脏病学[M].北京:北京出版社,1998:713-714.
[8]陈树宝.先天性心脏病影像诊断学[M].北京:人民卫生出版社,2004:237-244.
[9]Schrader M and Schulz-Knappe P.Peptidomics technologies for human body fluids.Trends Biotechnol.2001;19(10 Suppl):S55-S60.
[10]Kennedy S.Proteomic profiling from human samples:the body fluid alternative.Toxicol.Lett.2001;120(1-3):379- 384.
[11]Liotta LA,Ferrari M,Petricoin EF.Written in blood.Nature,2003;425(6961):905.
[12]Banks RE,Stanley AJ,Cairns DA,et al.Influences of Blood Sample Processing on Low-Molecular-Weight Proteome Identified by Surface-Enhanced Laser Desorption/Ionization Mass Spectrometry.Clin Chem,2005;51(9):1637-1649.
[13]Thadikkaran L,Siegenthaler MA,Crettaz D,et al.Recent advances in blood-related proteomics.Proteomics,2005;5(12):3019-3034.
[14]Cnorads TP,Hood BL,Issaq HJ,et al.Proteomic patterns as a diagnostic tool for early-stage cancer:a review of its progress to a clinically relevant tool.Molecular Diagnosis,2004;8(2):77-85.
[15]Bons,Judith A.P.;Wodzig,Will K.W.H.;van Dieijen-Visser,Maria P.Protein profiling as a diagnostic tool in clinical chemistry:a review.Clinical Chemistry & Laboratory Medicine.2005;43(12):1281-1290.
[16]Aivado M,Spentzos D,Alterovitz G,et al.Optimization and evaluation of surface-enhanced laser desorption/ionization time-of-flight mass spectrometry(SELDI-TOF MS) with reversed-phase protein arrays for protein profiling.Clinical Chemistry & Laboratory Medicine.2005;43(2):133-140.
[17]Seibert V,Wiesner A,Buschmann T,et al.Surface-enhanced laser desorption ionization time-of-flight mass spectrometry(SELDI TOF-MS) and ProteinChip~(?) technology in proteomics research.Pathology,Research and Practice,2004;200(2):83-94.
[18]Kas K.On the technicalities of discovering and applying protein biomarkers for cancer prevention.European Journal of Cancer Prevention,2004;13(5):437-446.
[19]Kang X,Xu Y,Wu X,et al.Proteomic Fingerprints for Potential Application to Early Diagnosis of Severe Acute Respiratory Syndrome.Clinical Chemistry,2005;51(1):56-64.
[20]Seibert Y,Ebert M and Buschmann T.Advances in clinical cancer proteomics:SELDI-ToF-mass spectrometry and biomarker discovery.Briefings in Functional Genomics and Proteomics,2005;4(1):16-26.
[21]Rocken C,Ebert MPA,Roessner A.Proteomics in pathology,research and practice.Pathology,Research and Practice,2004;200(2):69-82.
[22]Zhou XH,Obuchowski NA,McClish DK.Statistical methods in diagnostic medicine[M].北京:人民卫生出版社,2005:P46.
[23]王建华.实用医学科研方法[M].北京:人民卫生出版社,2003:191.
[24]Luo X,Carlson K A,Wojna V.et al.Macrophage proteomic fingerprinting predicts HIV-1-associated cognitive impairment.Neurology,2003;60(12):1931-1937.
[25]Papadopoulos MC,Abel PM,Agranoff D,et al.A novel and accurate diagnostic test for human African trypanosomiasis.The Lancet,2004;363(9418):1358-1363.
[26]Tomohiko H,Kazufumi H,Masaya O,et al.Identification of 2 serum biomarkers of renal cell carcinoma by surface enhanced laser desorption/ionization mass spectrometry.The Journal of Urology,2005;174(4,part 1 of 2):1213-1217.
[27]肖雪媛,卫秀平,何大澄.应用蛋白质芯片技术从血清中筛选肺癌标志蛋白.中国科学(C辑),2003:33(4):323-328.
[28]Schwegler EE,Cazares L,Steel LF,et al.SELDI-TOF MS Profiling of Serum for Detection of the Progression of Chronic Hepatitis C to Hepatocellular Carcinoma.Hepatology,2005;41(3):634-642.
[29]孙太欣,彭国光.蛋白质芯片在神经系统疾病进展评估和发病机制研究中的应用与作用.中国临床复,2005:9(21):178-180.
[30]Diamandis EP.Mass spectrometry as a diagnostic and a cancer biomarker discovery tool:opportunities and potential limitations.Mol Cell Proteomics,2004;3(4):367-78.
[31]胡跃,张苏展,余捷凯,等.血清蛋白质组图谱和人工神经网络软件在乳腺癌诊断中的应用.癌症,2005;24(1):67-71.
[32]Lancashire L,Schmid O,Shah H,et al.Classification of bacterial species from proteomic data using combinatorial approaches incorporating artificial neural networks,cluster analysis and principal components analysis.Bioinformatics,2005;21(10):2191-2199.
[33]Le L,Chi K,Tyldesley S,et al.Identification of serum amyloid a as a biomarker to distinguish prostate cancer patients with bone lesions.Clinical Chemistry, 2005;51(4):695-707.
[34]Petricoin EF, Ardekani AM, Hitt BA, et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet, 2002;359(9036):572-577.
[35]Carlson SM, Najmi A, Whitin JC, et al. Improving feature detection and analysis of surface-enhanced laser desorption/ionization-time of flight mass spectra. Proteomics, 2005; 5(11):2778-2788.
[36]Li L, Umbach DM, Terry P, et al. Application of GA/KNN method to SELDI proteomics data. Bioinformatics, 2004;20(10):1638-1640.
[37]Tong W, Xie Q, Hong H, et al. Using Decision Forest to Classify Prostate Cancer Samples on the Basis of SELDI-TOF MS Data: Assessing Chance Correlation and Prediction Confidence. Environments Health Respectives,2004; 112(16):1622-1627.
[38]Rogers MA, Clarke P, Noble J, et al. Proteomic profiling of urinary proteins in renal cancer by surface enhanced laser desorption ionization and neural-network analysis: identification of key issues affecting potential clinical utility. Cancer Res 2003;63(20):6971-83.
[39]Coombes KR. Analysis of Mass Spectrometry Profiles of the Serum Proteome.Clin Chem,2005; 51(1):1-2.
[1]CDC Use of folic acid for prevention of Spina Bifida and other neural tube defects-1983-1991.MMWR 1991;40:513.
[2]Torf CP,Katz EA,Bateson TF,et al.Maternal medications and environmental exposures as risk factors for gastroschisis.Teratology,1996;54(2):84-92.
[3]张波,刘天锡,贾江云,等.87例新生儿先天畸形配比研究.中华流行病学,1993:14(2):92.
[4]代礼,朱军.1996-2000年全国神经管畸形的动态监测.中华预防医学杂志,2002:36(6).402-404.
[5]李常惠,尚涛,田崇阳.309例神经管缺陷围产儿相关因素分.中国妇幼儿保健,2004:12(19):69-71.
[6]Daly LE,Kirke PN,Molly A,et al.Folate level and neural tube defects:implication for prevention.JAMA,1995,274:1689.
[7]Achor M,Alonso Aperte E,Reyes Let al.High-dose folic acid supplementation in rats effects on gestation and the methionine cycle.Br J Nutr,2000,83(2):177.
[8]Petridou E,Koussouri M,Toupadaki N,et al.Risk factors for cerebralpalsy:a case-control study in Greence.Scand-J-Soc-Med,1996,24(1):14-26.
[9]谢妮,陈利玉,戴橄,等.人巨细胞病毒ADl69株引起小鼠脑部畸形的初步探讨.湖南医科大学学报,2003,28(3):243-246.
[10]宋丽,路爱芝,朱庆义.神经管畸形的病因探讨及预防.中国优生与遗传杂志,2001,9(2):88-89.
[11]J C S Dean,H hailey,S J Moore,et al.Long term health and neuro development in children exposed to antiepileptic drugs before birth.Journal of Medical Genetics,2002;39:251-259.
[12]Norgard B,Puho E,Czeizel AE,et al.Aspirinuse during early pregnancy and the risk of congenital abnormalities:apopulation-based case-control study.Am J Obstet Gynecol,2005,192(3):992-923.
[13]Loeken MR.Current perspectives on the causes of neuraltube defects resulting form diabetic pregnancy.Am J Med Genet C Semin Med Genet,2005;135(1):77-87.
[14]Snell LH,Haughey BP,Buck G,Marecki MA.Metabolic crisis:hyperemesis gravidarum.J Perinat Neonatal Nurs.1998 Sep;12(2):26-37.
[15]吴艳乔,张迅,包广泽,等.我国南方神经管缺陷病因学初探.中华医学遗传学杂志,1994:11(4):210.
[16]Czeizel Ae,Dobo M,Vargha P.Hungarian cohort-controlled trial of periconceptional multivitamin supplementation shows a reduction incertain congenital abnormalities.Birth Defects Res A Clin Mol Teratiol,2004,70(1):853-861.
[17]孙庆芝,柏松,崔炼,等.长期饮酒对男性生殖系统功能影响.沈阳医学院报,1999:1(1):36-39.
[18]李常惠,尚涛,田崇阳.309例神经管缺陷围产儿相关因素分.中国妇幼儿保健,2004:12(19):69-71.
[19]Wennborg H,Magnusson LL,Bonde JP,et al.Congenital malformations related to maternal exposure to specific agents in biomedical research laboratories.J Occup Environ Med,2005;47(1):11-19.
[20]Logman JF,deVries LE,Hemels ME,et al.Patrnal organi csolvent exposure and adverse pregnancy outcomes:ameta-analysis.Am J Ind Med,2005;47(1):37-44.
[1]Hibbard ED,Smitheiis RW.Folic acidmetabolism and human embryopathy.Lancet,1995;345(12):149-151.
[2]Goyett P,Sumner JS,Frosstp,et al.Human methylenetetrahydrofolate reductase:isolation of cDNA,mapping and mutation identification.Nat Gentet,1994;7(4):551.
[3]Steegers-Theunissen RPM,Boers GHJ,Trijbels FJM,et al.Maternal hyperhomocysteinemia:a risk factor for neural-tube defects.Metabolism,1991;43:1475-1480.
[4]Mills JL,McPanlin JM,Kirke PN,et al.Homocysteine metabolism in pregnancies complicated by neural-tube defects.Lancet,1995;345:149-151.
[5]朱慧萍,李竹.中国人MTHFR基因多态性与神经管畸形遗传易感性遗传.2000:22(4):236-238.
[6]郑冬梅,程丽坤,薛雅丽,等.MTHFR基因多态与神经管缺陷的关系哈尔滨医科大学学报.2001:35(2):113-115.
[7]赵如冰,朱慧萍,刀京晶.胱硫脒B合酶基因多态性与神经管畸形的关系研究.卫生研究,2000:29(1):50-51
[8]MotulskyAG,Nutritional ecogenetics:homocysteine-related arteriosclerotic vascular disease,neural tube defects,and folic acid.Am J Hum Genet,1996;58:17
[9]李勇,李竹,陈星,等.同型半胱氨酸诱发鸡胚神经管畸形及叶酸的保护作用.卫生研究,1998:27(6):372-376
[10]Frosst P,Blom HJ,Milos R,et al.A candidate genetic risk factor for vascular disease:a common mutation in methylenetetrahydrofolate reductase.Nat.Genet.1995;10:111-113
[11]Whitehead AS,Gallagher P,Mills JL.et al.A genetic defect in 5,10-methylenetetrahydrofolate reductase in neural tube defects.Q JM, 1995,88:763-766.
[12]Molly AM.Folate bioavailability and health.Int J Vitam Nutr Res 2002;72(1):46-52.
[13]Angchaisuksiri P,Pingsuthiwong S,Sura T,et al.Prevalence of the C677T methylenetetra- hydrofolate reductase mutation in Thai patients with deep vein thrombosis.Acto Haematol,2000;103:191-196.
[14]Fletcher O,Keosling AM.MTHFR association with vascular disease? Hum Genet 1998;103(1) 11-12.
[15]梁剑宁,陈盛强.143例正常人亚甲基四氢叶酸还原酶基因的检测.广州医学院学报.2002:30(1):38-40.
[16]裴丽君,朱慧萍.中国汉蒙两族人群MTHFR基因热敏感性多态性分布的比较.遗传,2000:22(6):369-371.
[1]Cabrera RM,Hill DS,Etheredge AJ,et al.Investigations into the etiology of neural tubed efects.Birth Defects Res CEmbryo Today,2004;72(4):330-344.
[2]代礼,朱军,周光萱,等.1996-2000年全国神经管缺陷的动态监测.中华预防医学杂志,2002:36(6):402-405.
[3]肖坤蚵.国内井出生缺暗概况.实用妇产科杂志,1989:5(1):1-3.
[4]李竹,李橙.中国妇女妊娠前后单纯服用叶酸 对神经管畸形的预防效果.中华医学杂志,2004:7(7):493-497.
[5]王巧梅,叶馥莉.神经臂畸形的预防.中国优生与遗传杂志,2001:8(1):9-10.
[6]秦新华.妇女增补叶醺预防神经管畸形推广工作信息[C].北京:北京医科大学-美国疾病控树中心合作项目办公室(项目通讯),1998:(1):12-13.
[7]CDC,Recommedation for the use of folic acid to reduse the number of cases of spina bifida and other neural tube defects MMWR,1992,41:1-7.
[8]高树生,洪渝,刘月旺,等.正常妊娠叶酸和维生素B12水平的动态变化.中华围产医学杂志,2002:5(1):56-57.
[9]Brown JE,Jacobs DR,Hartman TJ,et al.Predictors of Red cell folate level in women attending pregnancy.JAMA,1997;277:548.
[10]王竹.部分食物中叶酸含量和北京居民叶酸摄入量.营养学报2001:23(1).88-90.
[11]Itikala PR,Watkins ML,Mulinare J,et al.Maternal multivitamin use and orofacial clefts in offspring.Teratology,2001;63(2):79-86.
[12]任爱国,张乐,李智文,等.围孕期预防胎儿神经管畸形增补叶酸的剂量和安全性.中国生育健康杂志,2004:15(6):35-37.
[13]Scholl TO,Johnson WG.Folic Acid:influence of outcome of pregnancy.Am J Clin Nutr.2000,71(suppl):1295-1303.
[14]Parul Christian,Subarna KK,Joanne Katz,et al.Effects of alternative maternal micronutrient supplements on low birth weight in rural Nepal: double blind randomised community trial.BMJ,2003;32(6)6:115-9.
[15]陈利,桂宝芬,张丽萍,等.云南省用叶酸预防先天出生缺陷的现状和对策.中国初级卫生保健,2003:17(4):41-43
[16]Health Education Authority.Changing preconceptions,Vol 2.Research report London:HEA,1998.
[17]Scholl TO,Hediger ML,schall JI,et al.Oietary and serum folate:their influence on the outcome of pregnancy..Ame J Clin Nutr,1996;63(4):520
[18]孙红,王留娣.孕期血清叶酸水平与早产、婴儿出生体重的关系.重庆医学,2002;31(7):595-596.
[19]Wickremasinghe VP,Prageeth PP,Pulleperuma DS,et al.Preconceptional care of women at booking visit at De Soysa Maternity Hospital and Castle Street Hospital for Women.Ceylon Med J.2003;48(3):77-9.
[20]De Wals P,Rusen IO,Lee NS,et al.Trend in prevalence of neural tubedefects in Quebec.Birth Defects Res Part A Clin Mol Teratol.2003;67(11):919-23.
[21]石杭.面粉中适量添加营养素以增加营养 环球时报,2003,11月
[1]HOFFMAN JI,KAPLAN S.The incidence of congenital heart disease.J Am Coll Cardiol,2002:39(12):1890-1900.
[2]BURKI MK,BABAR GS.Prevalence and pattern of congenital heart disease in Hazara.J Ayub Med Coll Abbottabad,2001:13(1):16-18.
[3]杨江帆,许月珍,李萍,等.嘉兴市20436例新生儿先天性心脏病流行病学调查.中华儿科杂志,1997:35(8):417-420.
[4]GOLDMUNTZ E.The epidemiology and genetics of congenital heart disease.Clin Perinatol,2001:28(1):1210.
[5]GREENE K,PRIESTLEY MD,WATERS J,etal.Detailed mapping of a congenital heart disease gene in chromosome 3p25.J Med Genet,2000:37(8):581-587.
[6]GELB BD.Recent advances in the understanding of genetic causes of congenital heart defects.Front Biosci,2000;5:D321-333.
[7]GELB BD.Genetic basis of syndromes associated with congenital heart disease.Curt Opin Cardiol,2001:16(3):188-194.
[8]VAUGHAN CJ,BASSON CT.Molecular determinants of atrial and ventricular septal defects and patent ductus arteriosus.Am J Med Genet,2000;97(4):304-309.
[9]LI D,AHMAD F,GARDNER MJ,etal.The locus of a novel gene responsible for arrhythmogenic right-ventricul ardysplasia characterized by early on set and high penetrance maps to chromosome 10p12-p14.Am J Hum Genet,2000;66(1):148-156.
[10]BAMFORD RN,ROESSLER E,BURDINE RD,etal.Loss-of-function mutations in the EGF-CFC gene CFClare associated with human left-right laterality defects.Nat Genet,2000;26(3):365-369.
[11]SHI YR,HSIEH KS,WU JY,etal.Molecular analysis of syndromic congenital heart disease using short tandem repeat markers and semiquantitative polymerase chain reaction method.Pediatr Int,2002;44(3):2642268.
[12]GOLDMUNTZ E,GEIGER E,BENSON DW,etal.Nkx2.5 mutations in patients with tetralogy of fallot.Circulation,2001;104(21):2565-2568.
[13]ELDADAH ZA,HAMOS HA,BIERY NJ,et al.Familial tetralogy of fallot caused by mutation in the jaggedl gene.HumMol Genet,2001;10(2):163-169.
[14]SCHOTT JJ,BENSON DW,BASSON CT,et al.Congenital heart disease caused by mutations in the transcription factor NKX2-5.Science,1998;281:108-111.
[15]王晓明,张国成,韩美玉.B19病毒对先天性心脏病先天感染的探证及电镜观察.第四军医大学学报,2001:22(4):340-343.
[16]LOFFREDO CA,SILBERGELD EK,FERENC ZC,et al.Association of transposition of the great arteries in infants with maternal exposures to herbicides and rodenticides.Am J Epidemiol,2001;153(6):529-536.
[17]BOTTO LD,LOFFREDO C,SCANLONKS,et al.Vitamin A and cardiacout flow tract defects.Epidemiology,2001;12(5):491-496.
[18]BOTTO LD,MULINAR EJ,ERICKSON JO.Occurrence of congenital heart defects in relation to maternal multivitamin use.Am J Epidemiol,2000;151(9):878-884.
[19]岳凤珍,高秉仁.先天性心脏病家系的遗传学研究.中国优生优育,2001:12(2):57261.
[1]宋森涛,朱梁,王文静,等.应用SELDI-TOF-MS技术分析肝癌血清差异表达蛋白.实用癌症杂志,2004,19(6):601-604.
[2]邓昊,吴人亮,陈莹,等.应用组织芯片技术检测胃癌组织中PTEN、Survivin和p21ras蛋白的表达.华中科技大学学报(医学版),2006,35(3):284-287.
[3]Christophe Rosty,Laurence Christa,Scott Kuzdzal,et al.Identification of hepatocarcinoma-intestine-pancreas/pancreatitis-associated protein I as a biomarker for pancreatic ductal adenocarcinoma by protein biochip technology.Cancer research,2002,62:1868-1875.
[4]高春芳,赵光,宋国英,等.用飞行质谱技术筛选结直肠癌患者中特异性生物标志物的临床意义.中华检验医学杂志,2003,26(11):658-661.
[5]王全晖,高春芳,王秀丽,等.利用SELDI-TOF质谱技术分析大肠癌患者血清蛋白质谱的变化.中国病理生理杂志,2005,21(10):1896-1900.
[6]吴登龙,王文静,关明,等.表面增强激光解吸/离子化质谱蛋白质芯片技术在筛选肾癌患者尿液标记物中的应用.中华医学杂志,2004,84(13):1092-1095.
[7]Vlahou A,Schellhammer PF,Mendrinos S,et al.Development of a Novel Proteomic Approach for the Detection of Transitional Cell Carcinoma of the Bladder in Urine.Am J Pathol,2001,158(4):1491-1502.
[8]Wright GL,Cazares LH,Leunq SM,et al.Proteinchip(R)surface enhanced laser desorption/ionization(SELDI) mass spectrometry:a novel protein biochip technology for detection of prostate cancer biomarkers in complex protein mixtures.Prostate cancer Prostatic Dis,1999,2(5/6):264-276.
[9]Paweletz CP,Trock B,Pennanen M,et al.Proteomic patterns of nipple aspirate fluids obtained by SELDI-TOF:potential for new biomarkers to aid in the diagnosis of breast cancer.Dis Markers,2001,17(4):301-307.
[10]戴淑真,刘海霞,王斌,等.SELDI蛋白芯片技术筛选卵巢癌血清肿瘤标志物的研究.实用癌症杂志,2006,21(1):42-45.
[11]Wong YF,Cheung TH,Lo KW,et al.Protein profiling of cervical cancer by protein-biochips:proteomic scoring to discriminate cervical cancer from normal cervix.Cancer Lett,2004,211(2):227-234.
[12]Yang EC,Guo J,Diehl G,et al.Protein expression profiling of endometrial malignancies reveals a new tumor marker:chaperonin 10.J Proteome Res,2004,3(3):636-643.
[13]廖萍,王文静,朱佩云,等.SELDI-TOF-MS技术检测肺腺癌血清生物标志物.中国肿瘤,2006,15(4):258-261.
[14]Cho CS,Yip TT,Christine Y,et al.Serum protein chip profiling can identify new protein markers in the diagnosis of relapse 0f nasopharyngeal carcinoma.Proteomi cs,2002,(33):979-981.
[15]张妍,刘华林,王斌,等.利用SELDI-TOF-MS技术研究巨细胞病毒感染致婴儿肝炎综合征的血清蛋白标志物.世界华人消化杂志,2005,13(21):2549-2553.
[16]Zhang L,Yu W,He T,et al.Contribution of human alpha-defensin 1,2,and 3to the anti-HIV-1 activity of CD8 antiviral factor.Science,2002,298(5595):995-1000.
[17]Thulasiraman V,McCutchen-Maloney SL,Motin VL,et al.Detection and identifica- tion of virulence factors in Yersinia pestis using SELDI ProteinChip system.Biotechniques,2001,30(2):428-432.
[18]Seo GM,Kim SJ,Chai YG.Rapid profiling of the infection of Bacillus anthracis on human macrophages using SELDI-TOF mass spectroscopy.Biochem Biophys Res Commun,2004,325(4):1236-1239.
[19]Papadopoulos MC,Abel PM,Aqranoff D,et al.A novel and accurate diagnostic test for human African trypanosomiasis.Lancet,2004,363(9418):1358-1363.
[20]Kang X,Xu Y,Wu X,et al.Proteomic Fingerprints for Potential Application to Early Diagnosis of Severe Acute Respiratory Syndrome.Clin Chem,2005,51(1):56-64.
[21]魏晓真.利用飞行质谱法对急性心肌梗死血清标志物的研究.中国急救医学,2004,24(10):715-717.
[22]McBride MW,Graham D,Delles C,et al.Functional genomics in hypertension.Current Opinion in Nephrology and Hypertension,2006,15(2):145-151.
[23]Davies H,Lomas L,Austen B.Profiling of amyloid beta peptide variants using SELDI Protein Chip arrays.Biotechniques,1999,27(6):1258-1261.
[24]Wadsworth J.T,Somers K.D,Cazares L.H,et al.Serum protein profiles to identify head and neck.Clinical Cancer Research,2004,10(5):1625-1632.
[1]Cabrera RM,Hill DS,Etheredge AJ,et al.Investigations into the etiology of neural tube defects.Birth Defects Res C Embryo Today,2004;72(4):330-344.
[2]代礼,朱军,周光萱,等.1996-2000年全国神经管缺陷的动态监测.中华预防医学杂志,2002:36(6):402-405.
[3]谢妮,陈利玉,戴橄,等.人巨细胞病毒AD169株引起小鼠脑部畸形的初步探讨.湖南医科大学学报,2003:28(3):243-246.
[4]宋丽,路爱芝,朱庆义.神经管畸形的病因探讨及预防.中国优生与遗传杂志,2001:9(2):88-89.
[5]Tsuda T,Yoshida K,Ohashi S,et al.Arthrogryposis,hydranencephaly and cerebellar hypoplasia syndrome in neonatalcal vesresul ring form intrauterine infection with Aino virus.VetRes,2004;35(5):531-538.
[6]J C S Dean,H halley,S J Moore,et al.Long term health and neurodevelopment in children exposed to antiepileptic drugs before birth.Journal of Medical Genetics,2002,39:251-259.
[7]李勇,王维林,袁正伟,等.脊柱裂动物模型制作与胚胎发生缺制探讨.中华小儿外科杂志,2004:25(5):438-259.
[8]Norgard B,Puho E,Czeizel AE,et al.Aspirinuse during early pregnancy and the risk of congenital abnormalities:apopulation-based case-control study.Am J Obstet Gynecol,2005;192(3):992-923.
[9]Wennborg H,Magnusson LL,Bonde JP,et al.Congenital malformations related to maternal exposure to specific agents in biomedical research laboratories.J Occup Environ Med,2005;47(1):11-19.
[10]Logman JF,deVries LE,nemels ME,et al.Patrnal organic solvent exposure and adverse pregnancy outcomes:ameta-analysis.Am J Ind Med,2005;47(1):37-44.
[11]申华,冯杏.111例神经管畸形分析与预防对策的研究.中国优生与遗传杂 志,2002;10(1):107-118.
[12]Humpf HU,Voss KA.Effects of thermal food processing on the chemical structure and toxicity of fumonisin mycotoxins.Mol Nutr Food Res,2004,48(4):225-269.
[13]于丽,管英俊,李如江,等.高温致神经管畸形中bc12和bax变化的动物实验研究.潍坊医学院学报,2003,225(1):18-20.
[15]Moretti ME,Bar-Oz B,FriedS,et al.Maternal hyperthermia and the risk for neural tube defects in offspring:systematic review and meta-analysis.Epidemolgy,2005,16(2):216-219.
[16]Larsson L,Lindqvist PG.Low-impact exercise during pregnancy-a studyofsafety.ActaObstedGynecolScand,2005,84(1):24-38.
[17]Vieira AR,Castillotaucher S.Influence of maternal age on the risk for neural tube defects,ametaanalysis.Rey Med Chil,2005,133(1):62-70.
[18]Kazaura M,Lie RT,Skjaerven R,et al.Paternal ageand the risk of birth defects in Norway.Ann Epidemiol,2004,14(80):566-570.
[19]王东,于向民,李玲,等.被动吸烟诱导金黄地鼠神经管形成过程中细胞过度死亡.中国优生与遗传杂志,2005,13(2):115.
[20]Loeken MR.Current perspectives on the causes of neural tube defects resulting form diabetic pregnancy.Am J Med Genet C Semin Med Genet,2005,135(1):77-87.
[21]Ray JG,Wyatt PR,Vermeulen MJ,et al.Greater maternal weigh and the ongoing risk of neural tube defects after folic acid flour fortification.Obstet Gynecol,2005,105(2):261-265.
[22]Czeizel Ae,Dobo M,Vargha P.Hungarian cohort-controlled tria of periconceptional multivitamin supplementation shows a reduction incertain congenital abnormalities.Birth Defects Res A Clin Mol Teratiol,2004,70(1):853-861.
[23]shaw GM,Carmichalel SL,Yang W,et al.Periconceptional dietary intake of myo-inostiol and neural tube defects in offspring.Birth Defects Res A Clin Mol Teratol,2005,73(3):184-187.
[24]Ulman C,Taneli F,Oksel F,et al.Zinc-deficient sprouting blight potatoes and their possible relation with neural tube defects.Cell Biochen Funct,2005,23(1):69-72.
[25]carrillo-Ponce MdeL,Martinez-OrdazVA,Yelasco-Rodriguez VM,et al.Serum lead,cadium,and zinc levels in new borns with neural tube defects from apolluted zone in Mexico.Reprod Toxicol,2004,19(2):149-154.
[26]Cengiz B,Soyemezf,Ozturk E,et al.Serum zinc,selenium,copper,and lead levels in women sith second-trimester induced abortion resulting form neural tube defects:a preliminary study.Biol Trace Elem Res,2004,97(3):225-235.
[27]BlancoMunoz J,Lacasana M,BorjaAburto YH,et al.Socioeconomic factors and the risk of anencephaly in a Mexican population:a case-control study.Public Health Rep,2005,120(1):39-45.
[28]李常惠,尚涛,田崇阳.309例神经管缺陷围产儿相关因素分.中国妇幼儿保健,2004,12(19):69-71.
[1]代礼,朱军,周光萱,等.1996-2000年全国神经管缺陷的动态监测.中华预防医学杂志,2002:36:402-405.
[2]Mills JL,McPanlin JM,Kirke PN,et al.Homocysteine metabolism in pregnancies complicated by neural tube defects.Lancet,1995;345:149-151.
[3]Weisberg IS,Tran P,Christensen B,et al.A second genetic polymorphism in methylenetetrahydrofolate reductase associated with decreased enzyme activity.Mol Genet Metab,1998;64:169-172.
[4]Frosst P,Blom HJ,Milos R,et al.A candidate genetic risk factor for vascular disease:a common mutation in methylenetetra-hydrofolate reductase.Nat Genet,1995;10:111-113.
[5]Yamada K,Chen Z,Rozen R,et al.Effect of conlnlon polymorphisms on the properties of recombinant human methylenetetrahydrofolate reductase.Proc Nati Acad Sci,2001;98:14853-14858.
[6]De Marco P,Calevo MG,Moroni A,et al.Study of MTHFR and MS polymorphisms as risk factor for NTDs in the Italian population.J Hum Genet,2002:47:319-324.
[7]郭晓霞,高原原,詹思延,等.5,10-亚甲基四氢叶酸还原酶多态性与神经管畸形的病例对照研究.疾病控制杂志,2000:4:217-219.
[8]Hansen DK,Barbes SA,Grafton TF,et al.Antisense modulation of 5,10-methylenetetrahydrofolate reductase expression produces neural tube defects in mouse embryos.Reprod Toxical,2001;15:21-29.
[9]Gonzalez-Herrera L,Orozco-Orozco L,Del Angel R,et al.Frequency of the thermolabile variant C677T in the MTHFR gene and 1 k of association with neural tube defects in the State of Yucatan,Mexico.Clin Genet,2002;62:394-398.
[10]Williamson R.Prevention of birth defects:folic acid.Biol Res Nurs,2001;3:33-38.
[11]李竹,陈新,赵平,等.妇女增补叶酸预防神经管畸形推广研究五年成果和工作总结.中国公共卫生,2001:17:725-727.
[12]Molly AM.FOlate bioavailability and health.Int J Vitam Nutr Res,2002;72:46-52.
[13]Steergers-Theunisen RP,Boers GH,Tribels FJ,et al.Maternal hyperhomoeysteineia:a risk factor for neural tube defect.Metabo lism,1994;43:1475-1480.
[14]李勇,李竹,陈星,等。同型半胱氨酸诱发鸡胚神经管畸形及叶酸的保护作用.卫生研究,1998:27:372-376.
[15]Jacques PF,Selhub J,Boston AG,et al.The effect of folie acid fortification on plasma folate and total homocysteine concentrations.N Engl J Med,1999,340:1449-1454.
[16]Rader JI.FOlie acid fortification,folate status and plasma homocysteine.J Nutr,2002,132:2466-2470.
[17]Stephane B,Bruno T,Estelle C,et al.Hyperhomocysteinaemia,folate an d vitamin B12 in unsupplemented haemodialysis patients:effect of oral therapy with folie acid and vitamin B_12.Nephrol Dial Transplant,2002,17:455-461.
[18]Guttormen AB,Ueland PM,Nesthus L,et al.Determinants and vitamin responsiveness of intermediate hyperhomocysteinemia.The Hordaland Homocysteine Study.J Clin Invest,1996;98:2174.
[19]Weisberg IS,Jacques PF,Selhub J,et al.The 1298-C polymorphism in methylenetetrahydrofolate reductase(MTHFR):in vitro expression and association with homocysteine.Atherosclerosis,2001;156:409-415.
[20]Hanson NQ,Aras O,Yang F,et al.C677T and A1298C polymorphisms of the methylenetetrahydrofolate reductase gene:incidence and effect of combined genotypes on plasma fasting and post-methionine load homocysteine in vascular disease.Clin Chem,2001;47:661-666.
[21]Maria LS,Maire R,Maritta S,et al.Polymorphisms of key enzymes in homocysteine metabolism affect diet responsiveness of plasma homocysteine in healthy women.J Nutr,2001;131:2643-2647.
[22]郝玲,刘明珠,刘晓慧,等.血浆同型半胱氨酸与叶酸、维生素Blz及还原酶的关系.中华预防医学杂志,2000,34:22-24.
[2]黄越华,陈赤,曾萼.2000-2005年广西出生缺陷监测结果分析.应用预防医学,2006:12(6):367-368,344.
[3]朱军,周光萱,代礼,等.1996-2000年全国围产期先天性心脏病发生率的分析.四川大学学报(医学版),2004:35(6):875 877.
[4]仇小强,张志勇,覃益敏,等.广西壮族儿童先天性心脏病危险因素的配对研究.中国公共卫生学报,1999:18(3):132-134.
[5]王晓明,张国成,韩美玉,等.先天性心脏病心脏组织中TORCH病原基因的检测.中华实验和临床病毒学杂志,2001:15(2):176-178.
[6]Scanlon KS,Ferencz C,Loffredo CA,et al.Preconceptional folate intake and malformations of the cardiac outflow tract.Epidemiology,1998;9(1):95-98.
[7]杨江帆,许月珍,李萍,等.嘉兴市20436例新生儿先天性心脏病流行病学调查.中华儿科杂志,1997:35(8):417.
[8]Goyette P,Sumner JS,Milos R,et al.Human methylenetetrahydrofolate reductase:isolation of cDNA,mapping and mutation identification.Nat Genet,1994;7(2):195-200.
[9]刘虹,李松,叶鸿瑁,等.血浆同型半胱氨酸、叶酸、5,10-亚甲基四氢叶酸还原酶基因多态性与先天性心脏病的相关性研究.中华围产医学杂志,2002:5(2):102-105.
[10]Wenstrom KD,Johanning GL,Johnston KE,et al.Association of the C677T methylenetetrahydrofolate reductase mutation and elevated homocysteine levels with congenital cardiac malformations.Am J Obstet Gynecol,2001;184(5):806-812.
[11]Junker R,Kotthoff S,Vielhaber H,et al.Infant methylenetetrahydrofolate reductase 677TT genotype is a risk factor for congenital heart disease.Cardiovasc Res,2001;51(2):251-254.
[12]杨德业,张怀勤,黄伟剑,等.室间隔缺损新的相关基因-蛋白酪氨酸激酶的实验研究.中国病理生理杂志,2004:20(1):117-119.
[13]李勇,陈祥贵.应用基因芯片技术探讨小鼠胚胎心脏发育过程中的差异表达基因.疾病控制杂志,2003:7(4):291-296.
[14]R(o|¨)cken C,Ebert MPA,Roessner A.Proteomics in pathology,research and practice.Pathology,Research and Practice,2004:200(2):69-82.
[15]肖雪嫒,卫秀平,何大澄.应用蛋白质芯片技术从血清中筛选肺癌标志蛋白.中国科学(C辑),2003;33(4):323-328.
[16]Poon TC,Hui AY,Chan HL,et al.Prediction of liver fibrosis and cirrhosis in chronic hepatitis B infection by serum proteomic fingerprinting:a pilot study.Clinical Chemistry,2005:51(2):328-335.
[17]Torf CP,Katz EA,Bateson TF,et al.Maternal medications and environmental exposures as risk factors for gastroschisis.Teratology,1996:54(2):84-92.
[18]代礼,朱军.1996-2000年全国神经管畸形的动态监测.中华预防医学杂志,2002:36(6).402-404.
[19]Williamson R.Prevention of birth defects:folic acid,Biol Res Nurs,2001;3(1):33-38.
[20]李竹,陈新,赵平,等.妇女增补叶酸预防神经管畸形推广研究五年成果和工作总结.中国公共卫生,2001:17(8):725-727.
[1]Hoffman JI, Kaplan S. The incidence of congenital heart disease. J Am Coll Cardiol 2002;39(12):1890-900.
[2]Eugene Braunwald[主编],陈灏珠[主译].心脏病学.第5版,北京:人民卫生出版社,1999:809.
[3]Green EK, Priestley MD, Waters J, et al. Detailed mapping of a congenital heart disease gene in chromosome 3p25. J Med Genet 2000;37(8):581-7.
[4]Chung MY, Lu JH, Chien HP, et al. Chromosome 22qll microdeletion in conotruncal heart defects: clinical presentation, parental origin and de novo mutations. Int J Mol Med 2001;7(5):501-5.
[5]Shi YR, Hsieh KS, Wu JY, et al. Molecular analysis of syndromic congenital heart disease using short tandem repeat markers and semiquantitative polymerase chain reaction method. Pediatr Int 2002;44(3):264-8.
[6]Digilio MC, Marino B, CapolinoR, et al. Familial recurrence of nonsyndromic congenital heart defects in first degree relatives of patients with deletion 22q11.2. Am J Med Genet A 2005 Jan 24; [Epub ahead of print]
[7]Li D, Ahmad F, Gardner MJ, et al. The locus of a novel gene responsible for arrhythmogenic right-ventricular dysplasia characterized by early onset and high penetrance maps to chromosome 10pl2-pl4. Am J Hum Genet 2000;66(1):148-56.
[8]Digilio MC, Marino B, Giannotti A, et al. Heterotaxy with left atrial isomerism in a patient with deletion 18p. Am J Med Genet 2000;94(3):198-200.
[9]GiglioS, Graw SL, Gimelli G, et al. Deletion of a 5-cM region at chromosome 8p23 is associated with a spectrum of congenital heart defects. Circulation 2000;102(4):432-7.
[10]Zhu W, Shiojima I, Hiroi Y, et al. Functional analyses of three Csx/Nkx-2. 5 mutations that cause human congenital heart disease. J Biol Chem 2000;275(45):35291-6.
[11]Vaughan CJ,Basson CT.Molecular determinants of atrial and ventricular septal defects and patent ductus arteriosus.Am J Med Genet 2000;97(4):304-9.
[12]Goldmuntz E,Geiger E,Benson DW.NKX2.5 mutations in patients with tetralogy of fallot.Circulation 2001;104(21):2565-8.
[13]Reamon-Buettner SM,Borlak J.Somatic NKX2-5 mutations as a novel mechanism of disease in complex congenital heart disease.J Med Genet 2004;41(9):684-90.
[14]孙淼,邱广蓉,孙桂凤,等.人类单纯性先天性心脏病患者Nkx 2-5基因突变及表达的研究.中国医科大学学报2001:30(5):321-24.
[15]Lee Y,Song AJ,Baker R,et al.Jumonji,a nuclear protein that is necessary for normal heart development.Circ Res 2000;86(9):932-8
[16]Goldmuntz E,Bamford R,Karkera JD,et al.CFC1 mutations in patients with transposition of the great arteries and double-outlet right ventricle.Am J Hum Genet 2002;70(3):776-80.
[17]Eldadah ZA,Hamosh A,Biery NJ,et al.Familial Tetralogy of Fallot caused by mutation in the jaggedl gene.Hum Mol Genet 2001;10(2):163-9.
[18]McFadden DH,Charite J,Richardson JA,et al.A GATA-dependent right ventricular enhancer controls dHAND transcription in the developing heart.Development 2000;127(24):5331-41.
[19]Svensson EC,Huggins GS,Lin H,et al.A syndrome of tricuspid atresia in mice with a targeted mutation of the gene encoding Fog-2.Nat Genet 2000;25(3):353-6.
[20]Ware SM,Peng J,Zhu L,et al.Identification and functional analysis of ZIC3 mutations in heterotaxy and related congenital heart defects.Am J Hum Genet 2004;74(1):93-105.
[21]仇小强,覃益敏,谢晓宇,等.1286例先天性心脏病患儿致病因素的调查研究.同济医科大学学报1999:28(5):399-401.
[22]Carmichael SL,Shaw GM.Maternal life event stress and congenital anomalies.Epidemiology 2000;11(1):30-5.
[23]Loffredo CA,Silbergeld EK,Ferencz C,et al.Association of transposition of the great arteries in infants with maternal exposures to herbicides and rodenticides.Am J Epidemiol 2001;153(6):529-36.
[24]Botto LD,Loffredo C,Scanlon KS,et al.Vitamin A and cardiac outflow tract defects.Epidemiology 2001;12(5):491-6.
[25]Sze RW,Yutzey KE.The molecular genetic revolution in congenital heart disease.AJR Am J Roentgenol 2001;176(3):575-81.
[26]Scanlon KS,Ferencz C,Loffredo CA,et al.Preconceptional folate intake and malformations of the cardiac outflow tract.Epidemiology 1998:9(1):95-8.
[27]杨江帆,许月珍,李萍,等.妊娠初期增补叶酸预防新生儿先天性心脏病作用的观察.中华儿科杂志1998:36(8):488.
[28]Goyette P,Sumner JS,Milos R,et al.Human methylenetetrahydrofolate reductase:isolation of cDNA,mapping and mutation identification.Nat Genet 1994;7(2):195-200.
[29]Frosst P,Blom HJ,Milos R,et al.A candidate genetic risk factor for vascular disease:a common mutation in methylenetetrahydrofolate reductase.Nat Genet 1995;10(1):111-3.
[30]李勇,李松,陈光慧,等.HCY-2基因和同型半胱氨酸与鸡胚先天性心脏畸形发生的关系.中华医学杂志2000:80(2):131-34.
[31]Rosenquist TH,Ratashak SA,Selhub J.Homocysteine induces congenital defects of the heart and neural tube:effect of folic acid.Proc Natl Acad Sci USA 1996;93(26):15227-32.
[32]李秀昌,胡燕燕.同型半胱氨酸代谢异常的分子发病学机制研究进展.国外医学遗传学分册2000:23(5):261-63.
[33]Tsai MY,Garg U,Key NS,et al.Molecular and biochemical approaches in the identification of heterozygotes for homocystinuria.Atherosclerosis 1996:122(1):69-77.
[34]王培林[主编].遗传病学.北京:人民卫生出版社2000:734-50.
[35]Chien KR.Genomic circuits and the integrative biology of cardiac diseases.Nature 2000;407(6801):227-32.
[36]刘虹,李松,叶鸿瑁,等.血浆同型半胱氨酸、叶酸、5,10-亚甲基四氢叶酸还原酶基因多态性与先天性心脏病的相关性研究.中华围产医学杂志2002:5(2):102-04.
[37]Wenstrom KD,Johanning GL,Johnston KE,et al.Association of the C677T methylenetetrahydrofolate reductase mutation and elevated homocysteine levels with congenital cardiac malformations.Am J Obstet Gynecol 2001;184(5):806-12;discussion 812-7.
[38]Guitti JC.Epidemiological characteristics of congenital heart diseases in Londrina,Parana south Brazil.Arq Bras Cardiol 2000;74(5):395-404.
[39]Arbour L,Gilpin C,Millor-Roy V,et al.Heart defects and other malformations in the Inuit in Canada:a baseline study.Int J Circumpolar Health 2004;63(3):251-66.
[40]刘薇延,宁寿葆,华邦杰,等.上海市杨浦、徐汇区小儿先天性心脏病发病率及其特点.中华儿科杂志1995;33(6):347-49.
[41]杨江帆,许月珍,李萍,等.嘉兴市20436例新生儿先天性心脏病流行病学调查.中华儿科杂志1997:35(8):416-19.
[42]Jacobs EG,Leung MP,Karlberg J.Birthweight distribution in southern Chinese infants with symptomatic congenital heart disease.J Paediatr Child Health 2003;39(3):191-6.
[43]Kecskes Z,Cartwright DW.Poor outcome of very low birthweight babies with serious congenital heart disease.Arch Dis Child Fetal Neonatal Ed 2002:87(1):F31-3.
[44]Goyette P,Pal A,Milos R,et al.Gene structure of human and mouse methylenetetrahydrofolate reductase(MTHFR).Mamm Genome 1998:9(8):652-6.
[45]Mukherjee M,Joshi S,Bagadi S,et al.A low prevalence of the C677T mutation in the methylenetetrahydrofolate reductase gene in Asian Indians.Clin Genet 2002:61(2):155-9.
[46]Kang SS,Wong PW,Susmano A,et al.Thermolabile methylenetetrahydrofolate reductase:an inherited risk factor for coronary artery disease.Am J Hum Genet 1991:48(3):536-45.
[47]De Franchis R,Mancini FP,D'Angelo A,et al.Elevated total plasma homocysteine and 677C-->T mutation of the 5,10-methylenetetrahydrofolate reductase gene in thrombotic vascular disease.Am J Hum Genet 1996:59(1):262-4.
[48]Motulsky AG.Nutritional ecogenetics:homocysteine-related arteriosclerotic vascular disease,neural tube defects,and folic acid.Am J Hum Genet 1996:58(1):17-20.
[49]朱慧萍,赵如冰,刀京晶,等.中国北方少数民族人群同型半胱氨酸代谢酶的遗传多态性.中国优生优育2000:11(2):51-53.
[50]于佳梅,王新春,陈白滨,等.中国5个民族亚甲基四氢叶酸还原酶基因多态性的研究.人类学学报1998:17(3):242-45.
[51]Kraus JP,Oliveriusova J,Sokolova J,et al.The human cystathionine beta-synthase(CBS) gene:complete sequence,alternative splicing,and polymorphisms.Genomics 1998;52(3):312-24.
[52]Sokolova J,Janosikova B,Terwilliger JD,et al.Cystathionine beta-synthase deficiency in Central Europe:discrepancy between biochemical and molecular genetic screening for homocystinuric alleles.Hum Mutat 2001;18(6):548-9.
[53]Kumar KS,Govindaiah V,Naushad SE,et al.Plasma homocysteine levels correlated to interactions between folate status and methylene tetrahydrofolate reductase gene mutation in women with unexplained recurrent pregnancy loss.J Obstet Gynaecol 2003;23(1):55-8.
[54]Tanis BC,Blom HJ,Bloemenkamp DG,et al.Folate,homocysteine levels,methylenetetrahydrofolate reductase(MTHFR) 677C --> T variant,and the risk of myocardial infarction in young women:effect of female hormones on homocysteine levels.J Thromb Haemost 2004;2(1):35-41.
[55]Botto LD,Yang Q.5,10-Methylenetetrahydrofolate reductase gene variants and congenital anomalies:a HuGE review.Am J Epidemiol 2000;151(9):862-77
[56]Junker R,Kotthoff S,Vielhaber H,et al.Infant methylenetetrahydrofolate reductase 677TT genotype is a risk factor for congenital heart disease.Cardiovasc Res 2001;51(2):251-4.
[57]闫丽盈,李书琴,赵汉杰,等.父母MTHFR基因型与子代先天性心脏病的关系.疾病控制杂志2003:7(2):94-97.
[58]Li Y,Cheng J,Zhu WL,et al.Study of serum Hcy and polymorphisms of Hcy metabolic enzymes in 192 families affected by congenital heart disease.Beijing Da Xue Xue Bao 2005;37(1):75-80.
[59]Ueland PM,Refsum H,Stabler SP,et al.Total homocysteine in plasma or serum:methods and clinical applications.Clin Chem 1993;39(9):1764-79.
[60]赵如冰,李勇,陈星.同型半胱氨酸对体外培养大鼠胚胎生长发育的影响.卫生研究2001:30(1):34-36.
[61]James SJ,Pogribna M,Pogribny IP,et al.Abnormal folate metabolism and mutation in the methylenetetrahydrofolate reductase gene may be maternal risk factors for Down syndrome.Am J Clin Nutr 1999;70(4):495-501.
[62]Nygard O,Vollset SE,Refsum H,et al.Total homocysteine and cardiovascular disease.J Intern Med 1999;246(5):425-54.
[63]Alluri RV,Mohan V,Komandur S,et al.MTHFR C677T gene mutation as a risk factor for arterial stroke:a hospital based study.Eur J Neurol 2005;12(1):40-4.
[64]Brouwer IA,van Dusseldorp M,Thomas CM,et al.Low-dose folic acid supplementation decreases plasma homocysteine concentrations:a randomized trial.Am J Clin Nutr 1999;69(1):99-104.
[65]Jacques PF,Selhub J,Bostom AG,et al.The effect of folic acid fortification on plasma folate and total homocysteine concentrations.N Engl J Med 1999;340(19):1449-54.
[66]Bronstrup A,Hages M,Prinz-Langenohl R,et al.Effects of folic acid and combinations of folic acid and vitamin B-12 on plasma homocysteine concentrations in healthy,young women.Am J Clin Nutr 1998;68(5):1104-10.
[67]Botto LD,Mulinare J,Erickson JD.Occurrence of congenital heart defects in relation to maternal mulitivitamin use.Am J Epidemiol 2000;151(9):878-84.
[68]张泽峰,李竹,季成叶,等.孕早期精神受刺激对出生儿单纯性先心病发病的影响.中国公共卫生1999:15(4):307-08.
[69]Kim WG,Suh JW,Chi JG.Nitrofen-induced congenital malformations of the heart and great vessels in rats:an animal model.J Pediatr Surg 1999;34(12):1782-6.
[70]刘毓谷[主编].卫生毒理学基础.第2版 北京:人民卫生出版社1994:150.
[71]Wang X,Zhang G,Liu F,et al.Prevalence of human parvovirus B19 DNA in cardiac tissues of patients with congenital heart diseases indicated by nested PCR and in situ hybridization.J Clin Virol 2004;31(1):20-4.
[72]Bittencourt AL,Garcia AG.Pathogenesis and pathology of hematogenous infections of the fetus and newborn.Pediatr Pathol Mol Med 2002;21(4):353-99.
[73]仇小强,彭如宽,谢晓宇,等.儿童先天性心脏病各分型致病因素的多因多果研究.广西医科大学学报1999:16(4):415-17.
[74]Gittenberger-de Groot AC,Bartelings MM,Deruiter MC,et al.Basics of Cardiac Development for the Understanding of Congenital Heart Malformations.Pediatr Res 2005;57(2):169-76.
[1]Murray JC, Buetow KH, Weber JL, et al. A comprehensive human map with centimorgan density. Science, 1994; 265(5181):2049-2054.
[2]Hudson TJ, Stein LD, Gerety SS, et al. An STS based map of the human genome.Science, 1995; 270(5244):1945-1954.
[3]Lander ES, Linton LM, Birren B, et al. Initial sequencing and analysis of the human genome. Nature, 2001; 409(6822):860-921.
[4]Venter JC, Adams MD, Myers EW, et al. The sequence of the human genome.Science, 2001; 291(5507):1304-1351.
[5]Anderson L, Seilhamer J. A comparison of selected mRNA and protein abundances in human liver. Electrophoresis, 1997; 18(3-4):533-537.
[6]Anderson NL, Anderson NG. Proteome and proteomics: new technologies, new concepts, and new words. Electrophoresis, 1998; 19(11):1853-1861.
[7]Chen G, Gharib TG, Huang CC, et al. Discordant protein and mRNA expression in lung adenocarcinomas. Mol. Cell Proteomics, 2002; 1(4):304-313.
[8]Rubin MA. Understanding disease cell by cell. Science, 2002; 296(5571):1329-1330.
[9]Ball HJ and Hunt NH. Needle in a haystack: microdissecting the proteome of a tissue. Amino Acids, 2004; 27(1):1-7.
[10]Melle C, Ernst G, Schimmel B, et al. A technical triade for proteomic identification and characterization of cancer biomarkers. Cancer Research,2004; 64(12):4099-4104.
[11]Hudelist G, Singer CF, Kubista E, et al. Use of high-throughput arrays for profiling differentially expressed proteins in normal and malignant tissues. Anti-Cancer Drugs,2005; 16(7):683-689.
[12]Service RF. PROTEOMICS:high-speed biologists search for gold in proteins.Science, 2001; 294(5549):2074-2077.
[13]Seibert V,Wiesner A,Buschmann T,et al.Surface-enhanced laser desorption ionization time-of-flight mass spectrometry(SELDI TOF-MS) and ProteinChip~(?) technology in proteomics research.Pathology,Research and Practice,2004:200(2):83-94.
[14]Rosenblatt KP,Bryant-Greenwood P,Killian JK,et al.Serum proteomics in cancer diagnosis and management.Annual Review of Medicine,2004:55(1):97-112.
[15]修瑞娟。微血管医学与蛋白质组学。中国微循环,2004;8(2):69-71.
[16]Wiesner A.Detection of Tumor Markers with ProteinChip~(?) Technology.Current Pharmaceutical Biotechnology,2004;5(1):45-67.
[17]Yasui Y,Pepe M,Thompson ML,et al.A data-analytic strategy for protein biomarker discovery:profiling of high-dimensional proteomic data for cancer detection.Biostatistics,2003:4(3):449-463.
[18]Boguski MS,Mclntosh MW.Biomedical informatics for proteomics.Nature,2003;422(6928):233-237.
[19]Rocken C,Ebert MPA,Roessner A.Proteomics in pathology,research and practice.Pathology,Research and Practice,2004;200(2):69-82.
[20]Wasinger VC,Cordwell SJ,Cerpa-Poljak C,et al Progress with gene-product mapping of the Mollicutes:Mycopiasma genitalium Electrophoresis,1995;16(7):1090-1094.
[21]Peng J,Gygi SP.Proteomics:The move to mixtures.J Mass Spectrom,2001;36(10):1083 - 1091.
[22]Takahashi N,Kaji H,Yanagida M,et al.Proteomics:Advanced technology for the analysis of cellular functionl,2.The Journal of Nutrition,2003;133(6S-I):2090-2096.
[23]Pardanani A,Wieben ED,Spelsberg TC,et al.Primer on medical genomics part Ⅳ:Expression proteomics.Mayo Clinic Proceedings,2002;77(11): 1185-1196.
[24]Zhu H,Bilgin M,Bangham R,et al.Global analysis of protein activities using proteome chips.Science,2001;293(5537):2101-2105.
[25]Amacher DE,Adler R,Herath A,et al.Use of Proteomic Methods to Identify Serum Biomarkers Associated with Rat Liver Toxicity or Hypertrophy.Clinical Chemistry,2005;51(10):1796-1803.
[26]Reymond MA,Steinert R,Kahne T,et al.Expression and functional proteomics studies in colorectal cancer.Pathology,Research and Practice,2004;200(2):119-127.
[27]Hanash S.Disease proteomics.Nature,2003;422(6928):226-232.
[28]Smith DL,Evans CA,Pierce A,et al.Changes in the proteome associated with the action of berabl tyrosine kinase are not related to translational regulation.Mol Cell Proteomics,2002;1(11):876-884.
[29]蔡春,蔡康荣,徐美奕.肝靶向药物载体半乳糖基蛋白的合成及其特性研究。广东医学院学报,2005:23(3):235-237.
[30]Service RF.Gene and protein patents get ready to go head to head.Science,2001;294(5549):2082-2083.
[31]Cho A and Normile D.Nobel Prize in Chemistry.Mastering macromolecules.Science,2002;298(5593):527-528.
[32]Hutchens TW,Yip TY.New desorption strategies for the mass spectrometric analysis of macromolecules.Rapid Commun Mass Spectrom,1993;7(1):576-580.
[33]Tang N,Tornatore P,Weinberger SR.Current developments in SELDI affinity technology.Mass Spectrom Rev,2004;23(1):34-44.
[34]张建中,郑燕华,冯凯,等.SELDI蛋白指纹技术在肿瘤早期诊断中的应用.世界华人消化杂志,2004:12(12):2773-2777.
[35]Issaq HJ,Ueenstra TD,Conrads TP,et al.The SELDI-TOF MS approach to proteomics:protein profiling and biomarker identification.Biochem Biophys Res Commun, 2002; 292(3):587-592.
[36]Grizzlea WE, Adamb BL, Bigbee WL, et al. Serum protein expression profiling for cancer detection: Validation of a SELDI-based approach for prostate cancer. Disease Markers, 2004; 19(4/5):185-195.
[37]Solassol J, Boulle N, Maudelonde T, et al. Clinical proteomics: towards early detection of cancers. Med Sci (Paris). 2005;21(8-9):722-729.
[38]Seibert V, Ebert M and Buschmann T. Advances in clinical cancer proteomics:SELDI-ToF-mass spectrometry and biomarker discovery. Briefings in Functional Genomics and Proteomics, 2005; 4(1):16-26.
[39]von Eggeling F, Junker K, Fiedle W, Wollscheid V, Durst M, Claussen UE.Mass spectrometry meets chip technology: a new proteomic tool in cancer research? Electrophoresis 2001; 22(14):2898-2902 .
[40]Karsan A, Eigl BJ, Flibotte S, Gelmon K, et al. Analytical and preanalytical biases in serum proteomic pattern analysis for breast cancer diagnosis. Clinical Chemistry, 2005; 51(8):1525-1528.
[41]Check E. Proteomics and cancer: running before we can walk? Nature 2004;429(6991):496-497.
[42]Garber K. Debate rages over proteomic patterns. Journal of the National Cancer Institute, 2004;96(11):816-818.
[43]Diamandis EP. Analysis of Serum Proteomic Patterns for Early Cancer Diagnosis:Drawing Attention to potential problems. Journal of the National Cancer Institute, 2004; 96 (5):353-357.
[44]Baggerly KA, Morris JS, Edmonson SR, et al. Signal in noise: evaluating reported reproducibility of serum proteomic tests for ovarian cancer.Journal of the National Cancer Institute, 2005; 97(4):307-309.
[45]Malyarenko DI, Cooke WE, Adam BL, et al. Enhancement of Sensitivity and Resolution of Surface-Enhanced Laser Desorption/Ionization Time-of-Flight Mass Spectrometric Records for Serum Peptides Using Time-Series Analysis Techniques.Clinical Chemistry,2005;51(1):65-74.
[46]孙太欣,彭国光.蛋白质芯片在神经系统疾病进展评估和发病机制研究中的应用与作用.中国临床康复,2005:9(21):178-180.
[47]Rai AJ,Gelfand CA,Haywood BC,et al.HUPO Plasma Proteome Project specimen collection and handling:towards the standardization of parameters for plasma proteome samples.Proteomics,2005;5(13):3262-3277.
[48]Hoffman JI,Kaplan S.The incidence of congenital heart disease.J Am Coll Cardiol,2002;39(12):1890-1900.
[49]王惠珊,袁雪,闫淑娟,等.北京市1992-2000年婴儿及胎婴儿死亡率的监测与干预研究.中华医学杂志,2001;81(23):1424-1426.
[50]朱军,周光萱,代礼,等.1996-2000年全国围产儿先天性心脏病发生率的分析.四川大学学报(医学版),2004:36(6):875-877.
[51]蒋立虹,段昌群,马志强.先天性心脏病流行病学调查研究动态.华西医学,2004:19(3):510-511.107
[52]仇小强,张志勇,覃益敏,等.广西壮族儿童先天性心脏病危险因素的配对研究[J].中国公共卫生学报,1999;18(3):132-134.
[53]仇小强,覃益敏,谢晓宇,等.1286例先天性心脏病患儿致病因素的调查研究[J].同济医科大学学报,1999:28(5):399-401.
[54]Gilboa SM,Mendola P,Olshan AF,et al.Relation between Ambient Air Quality and Selected Birth Defects,Seven County Study,Texas,1997-2000.American Journal of Epidemiology,2005;162(3):238-252.
[55]Ritz B,Yu F,Fruin S,et al.Ambient Air Pollution and Risk of Birth Defects in Southern California.American Journal of Epidemiology,2002;155(1):17-25.
[56]Bateman DN,MaElhatton PR,Dickinson D,et al.A case control study to examine the pharmacological factors underlying ventricular septal defects in the North of England.European Journal of Clinical Pharmacology,2004;60(9):635-641.
[57]Hwang BF,Magnus P,Jaakkola JJK.Risk of Specific Birth Defects in Relation to Chlorination and the Amount of Natural Organic Matter in the Water Supply.American Journal of Epidemiology,2005;156(4):374-382.
[58]Bassili1 A,Mokhtar SA,Dabous NI,et al.Risk factors for congenital heart diseases in Alexandria,Egypt.European Journal of Epidemiology,2000;16(9):805-814.
[59]程光存,严中亚,吴一军,等.儿童先天性心脏病室间隔缺损致病因素分析.心肺血管病杂志,2004:23(4):208-210.
[60]Schott JJ,Beson D W,Basson CT,et al.Congenital heart disease caused by mutation in the transcription factor Nkx 2-5.Science,1998;281(5373):108-111.
[61]宫立国,邱广蓉,邱广斌,等.人类单纯性先天性心脏病中TBX5基因的突变及表达研究.遗传,2003:25(5):533-537.
[62]杨德业,张怀勤,黄伟剑,等.室间隔缺损新的相关基因-蛋白酪氨酸激酶的实验研究.中国病理生理杂志,2004:20(1):117-119.
[63]Kwon YT,Kashina AS,Davydov IV,et al.An essential role of N-terminal arginylation in cardiovascular development.Science,2002;297(5578):96-99.
[64]邱广蓉,孙桂凤,孙森,等.Hox基因与人类室间隔缺损相关性的研究.中华医学杂志,2001:81(3):174-175.
[65]邓伟国,付艳,谢铁男,等.小鼠叉头框C2基因变异致室间隔缺损.吉林大学学报(医学版),2004:30(1):6-9.
[66]李勇,陈祥贵.应用基因芯片技术探讨小鼠胚胎心脏发育过程中的差异表达基因.疾病控制杂志,2003:7(4):291-296.
[67]Brand M,kempf H,paul M,et al.Expression of endothelins in human cardiogenesis. Journal of Molecular Medicine, 2002; 80(11):715-723.
[68]Feng Q, Song W, Lu X, et al. Development of heart failure and congenital septal defects in mice lacking endothelial nitric oxide synthase.Circulation, 2002; 106(7):873-839.
[69]LeeY, Song AJ, Baker R, et al. Jumonji, a nuclear protein that is necessary for normal heart development. Circulation Research, 2000; 86(9): 932-938.
[70]Jung J, Kim TG, Lyons GE, et al. Jumonji Regulates Cardiomyocyte Proliferation via Interaction with Retinoblastoma Protein. J Biol Chem,2005; 280(35): 30916-30923.
[71]LiangX, Zhou Q, Li X, et al. PINCH1 Plays an Essential Role in Early Murine Embryonic Development but Is Dispensable in Ventricular Cardiomyocytes.Mol Cell Biol, 2005; 25(8):3056-3062.
[72]Law YM, Keller BB, Feingold BM, et al. Usefulness of plasma B-type natriuretic peptide to identify ventricular dysfunction in pediatric and adult patients with congenital heart disease. Am J Cardiol, 2005; 95(4):474-478.
[73]Chen H, Shi S, Acosta L, et al. BMP10 is essential for maintaining cardiac growth during murine cardiogenesis. Development, 2004; 131(9):2219-2231.
[74]Zhou HM, Weskamp G, Chesneau V, et al. Essential role for ADAM19 in cardiovascular morphogenesis. Mol Cell Biol, 2004;24(1):96-104.
[75]陈树宝主编.先天性心脏病影像诊断学[M].北京:人民卫生出版社, 2004: 237-244.
[76]Kang X, Xu Y, Wu X, et al. Proteomic Fingerprints for Potential Application to Early Diagnosis of Severe Acute Respiratory Syndrome[J]. Clinical Chemistry, 2005; 51(1):56-64.
[77]Li J, Zhang Z, Rosenzweig J, et al. Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer.Clinical Chemistry, 2002;48(8):1296-1304.
[78]Callen NA,Blackemore KJ,Kan JS.Counseling in congenital heart defects.Obstet Gynecol Surv,1991;46(10):651-655.
[79]Schrader M and Schulz-Knappe P.Peptidomics technologies for human body fluids.Trends Biotechnol.2001;19(10 Supp1):S55-S60.
[80]Liotta LA,Ferrari M,Petricoin EF.Written in blood.Nature,2003;425(6961):905.
[81]Thadikkaran L,Siegenthaler MA,Crettaz D,et al.Recent advances in blood-related proteomics.Proteomics,2005;5(12):3019-3034.
[82]Patterson SD.Proteomics:evolution of the technology.Biotechniques,2003;35(3):440-444.
[83]Zhu H,Snyder M.Protein chip technology.Curr Opin Chem Biol,2003;7(1):55-63.
[84]Aebersold R and Mann M.Mass spectrometry-based proteomics.Nature,2003;422(6928):198-207.
[85]Adkins JN,Varnum SM,Auberry KJ,et al.Toward a human blood serum proteome:analysis by multidimensional separation coupled with mass spectrometry.Mol Cell Proteomics.2002;1(25):947-955.
[86]Zolg JW,Langen H.How industry is approaching.the search for new diagnostic markers and biomarkers.Mol Cell Proteomics,2004;3(4):345-354.
[87]Kas K.On the technicalities of discovering and applying protein biomarkers for cancer prevention.European Journal of Cancer Prevention,2004;13(5):437-446.
[88]邓军,孔祥清,杨荣,等.室间隔缺损介入治疗前后可溶性细胞间黏附分子-1、P选择素、肌钙蛋白Ⅰ的变化及意义.南京医科大学学报(自然科学版),2005:25(8):555-557.
[89]Hortin GL.Can Mass Spectrometric Protein Profiling Meet Desired Standards of Clinical Laboratory Practice? Clin. Chem. 2005; 51(1):3-5.
[90]Banks RE, Stanley AJ, Cairns DA, et al. Influences of Blood Sample Processing on Low-Molecular-Weight Proteome Identified by Surface-Enhanced Laser Desorption/Ionization Mass Spectrometry. Clin Chem,2005; 51(9):1637 - 1649.
[91]Schwegler EE, Cazares L, Steel LF, et al. SELDI-TOF MS Profiling of Serum for Detection of the Progression of Chronic Hepatitis C to Hepatocellular Carcinoma. Hepatology, 2005; 41(3):634-642.
[92]Semmes OJ, Feng Z, Adam BL, et al. Evaluation of Serum Protein Profiling by Surface-Enhanced Laser Desorption/Ionization Time-of-Flight Mass Spectrometry for the Detection of Prostate Cancer: I. Assessment of Platform Reproducibility.Clinical Chemistry, 2005;51(1):102-112.
[93]Kiga C, Nakagawa T, Koizumi K, et al. Expression Patterns of Plasma Proteins in Spontaneously Diabetic Rats after Oral Administration of a Kampo Medicine, Hachimi-jio-gan, Using SELDI ProteinChip Platform. Biological & Pharmaceutical Bulletin, 2005;28(6):1031-1037.
[94]Papadopoulos MC, Abel PM, Agranoff D, et al. A novel and accurate diagnostic test for human African trypanosomiasis [J]. Lancet, 2004; 363(9418):1358-1363.
[95]Tomohiko H, Kazufumi H, Masaya O, et al. Identification of 2 serum biomarkers of renal cell carcinoma by surface enhanced laser desorption/ionization mass spectrometry. The Journal of Urology,2005;174(4, part 1 of 2): 1213-1217.
[1]朱军,周光萱,代礼,等.1996-2000年全国围产儿先天性心脏病发生率的分析.四川大学学报(医学版),2004:36(6):875-877.
[2]Pradat P,Francannet C,Harris JA,et al.The Epidemiology of Cardiovascular Defects,Part Ⅰ:A Study Based on Data from Three Large Registries of Congenital Malformations.Pediatric Cardiology,2003;24(3):195-221.
[3]蒋立虹,段昌群,马志强.先天性心脏病流行病学调查研究动态.华西医学,2004:19(3):510-511.
[4]惠玲.小儿先天性心脏病学[M].北京:北京出版社,1998:710.
[5]杨思源.小儿心脏学[M].北京:人民卫生出版社,2005:125.
[6]仇小强,覃益敏,谢晓宇,等.1286例先天性心脏病患儿致病因素的调查研究.同济医科大学学报,1999:28(5):399-401.
[7]王惠玲.小儿先天性心脏病学[M].北京:北京出版社,1998:713-714.
[8]陈树宝.先天性心脏病影像诊断学[M].北京:人民卫生出版社,2004:237-244.
[9]Schrader M and Schulz-Knappe P.Peptidomics technologies for human body fluids.Trends Biotechnol.2001;19(10 Suppl):S55-S60.
[10]Kennedy S.Proteomic profiling from human samples:the body fluid alternative.Toxicol.Lett.2001;120(1-3):379- 384.
[11]Liotta LA,Ferrari M,Petricoin EF.Written in blood.Nature,2003;425(6961):905.
[12]Banks RE,Stanley AJ,Cairns DA,et al.Influences of Blood Sample Processing on Low-Molecular-Weight Proteome Identified by Surface-Enhanced Laser Desorption/Ionization Mass Spectrometry.Clin Chem,2005;51(9):1637-1649.
[13]Thadikkaran L,Siegenthaler MA,Crettaz D,et al.Recent advances in blood-related proteomics.Proteomics,2005;5(12):3019-3034.
[14]Cnorads TP,Hood BL,Issaq HJ,et al.Proteomic patterns as a diagnostic tool for early-stage cancer:a review of its progress to a clinically relevant tool.Molecular Diagnosis,2004;8(2):77-85.
[15]Bons,Judith A.P.;Wodzig,Will K.W.H.;van Dieijen-Visser,Maria P.Protein profiling as a diagnostic tool in clinical chemistry:a review.Clinical Chemistry & Laboratory Medicine.2005;43(12):1281-1290.
[16]Aivado M,Spentzos D,Alterovitz G,et al.Optimization and evaluation of surface-enhanced laser desorption/ionization time-of-flight mass spectrometry(SELDI-TOF MS) with reversed-phase protein arrays for protein profiling.Clinical Chemistry & Laboratory Medicine.2005;43(2):133-140.
[17]Seibert V,Wiesner A,Buschmann T,et al.Surface-enhanced laser desorption ionization time-of-flight mass spectrometry(SELDI TOF-MS) and ProteinChip~(?) technology in proteomics research.Pathology,Research and Practice,2004;200(2):83-94.
[18]Kas K.On the technicalities of discovering and applying protein biomarkers for cancer prevention.European Journal of Cancer Prevention,2004;13(5):437-446.
[19]Kang X,Xu Y,Wu X,et al.Proteomic Fingerprints for Potential Application to Early Diagnosis of Severe Acute Respiratory Syndrome.Clinical Chemistry,2005;51(1):56-64.
[20]Seibert Y,Ebert M and Buschmann T.Advances in clinical cancer proteomics:SELDI-ToF-mass spectrometry and biomarker discovery.Briefings in Functional Genomics and Proteomics,2005;4(1):16-26.
[21]Rocken C,Ebert MPA,Roessner A.Proteomics in pathology,research and practice.Pathology,Research and Practice,2004;200(2):69-82.
[22]Zhou XH,Obuchowski NA,McClish DK.Statistical methods in diagnostic medicine[M].北京:人民卫生出版社,2005:P46.
[23]王建华.实用医学科研方法[M].北京:人民卫生出版社,2003:191.
[24]Luo X,Carlson K A,Wojna V.et al.Macrophage proteomic fingerprinting predicts HIV-1-associated cognitive impairment.Neurology,2003;60(12):1931-1937.
[25]Papadopoulos MC,Abel PM,Agranoff D,et al.A novel and accurate diagnostic test for human African trypanosomiasis.The Lancet,2004;363(9418):1358-1363.
[26]Tomohiko H,Kazufumi H,Masaya O,et al.Identification of 2 serum biomarkers of renal cell carcinoma by surface enhanced laser desorption/ionization mass spectrometry.The Journal of Urology,2005;174(4,part 1 of 2):1213-1217.
[27]肖雪媛,卫秀平,何大澄.应用蛋白质芯片技术从血清中筛选肺癌标志蛋白.中国科学(C辑),2003:33(4):323-328.
[28]Schwegler EE,Cazares L,Steel LF,et al.SELDI-TOF MS Profiling of Serum for Detection of the Progression of Chronic Hepatitis C to Hepatocellular Carcinoma.Hepatology,2005;41(3):634-642.
[29]孙太欣,彭国光.蛋白质芯片在神经系统疾病进展评估和发病机制研究中的应用与作用.中国临床复,2005:9(21):178-180.
[30]Diamandis EP.Mass spectrometry as a diagnostic and a cancer biomarker discovery tool:opportunities and potential limitations.Mol Cell Proteomics,2004;3(4):367-78.
[31]胡跃,张苏展,余捷凯,等.血清蛋白质组图谱和人工神经网络软件在乳腺癌诊断中的应用.癌症,2005;24(1):67-71.
[32]Lancashire L,Schmid O,Shah H,et al.Classification of bacterial species from proteomic data using combinatorial approaches incorporating artificial neural networks,cluster analysis and principal components analysis.Bioinformatics,2005;21(10):2191-2199.
[33]Le L,Chi K,Tyldesley S,et al.Identification of serum amyloid a as a biomarker to distinguish prostate cancer patients with bone lesions.Clinical Chemistry, 2005;51(4):695-707.
[34]Petricoin EF, Ardekani AM, Hitt BA, et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet, 2002;359(9036):572-577.
[35]Carlson SM, Najmi A, Whitin JC, et al. Improving feature detection and analysis of surface-enhanced laser desorption/ionization-time of flight mass spectra. Proteomics, 2005; 5(11):2778-2788.
[36]Li L, Umbach DM, Terry P, et al. Application of GA/KNN method to SELDI proteomics data. Bioinformatics, 2004;20(10):1638-1640.
[37]Tong W, Xie Q, Hong H, et al. Using Decision Forest to Classify Prostate Cancer Samples on the Basis of SELDI-TOF MS Data: Assessing Chance Correlation and Prediction Confidence. Environments Health Respectives,2004; 112(16):1622-1627.
[38]Rogers MA, Clarke P, Noble J, et al. Proteomic profiling of urinary proteins in renal cancer by surface enhanced laser desorption ionization and neural-network analysis: identification of key issues affecting potential clinical utility. Cancer Res 2003;63(20):6971-83.
[39]Coombes KR. Analysis of Mass Spectrometry Profiles of the Serum Proteome.Clin Chem,2005; 51(1):1-2.
[1]CDC Use of folic acid for prevention of Spina Bifida and other neural tube defects-1983-1991.MMWR 1991;40:513.
[2]Torf CP,Katz EA,Bateson TF,et al.Maternal medications and environmental exposures as risk factors for gastroschisis.Teratology,1996;54(2):84-92.
[3]张波,刘天锡,贾江云,等.87例新生儿先天畸形配比研究.中华流行病学,1993:14(2):92.
[4]代礼,朱军.1996-2000年全国神经管畸形的动态监测.中华预防医学杂志,2002:36(6).402-404.
[5]李常惠,尚涛,田崇阳.309例神经管缺陷围产儿相关因素分.中国妇幼儿保健,2004:12(19):69-71.
[6]Daly LE,Kirke PN,Molly A,et al.Folate level and neural tube defects:implication for prevention.JAMA,1995,274:1689.
[7]Achor M,Alonso Aperte E,Reyes Let al.High-dose folic acid supplementation in rats effects on gestation and the methionine cycle.Br J Nutr,2000,83(2):177.
[8]Petridou E,Koussouri M,Toupadaki N,et al.Risk factors for cerebralpalsy:a case-control study in Greence.Scand-J-Soc-Med,1996,24(1):14-26.
[9]谢妮,陈利玉,戴橄,等.人巨细胞病毒ADl69株引起小鼠脑部畸形的初步探讨.湖南医科大学学报,2003,28(3):243-246.
[10]宋丽,路爱芝,朱庆义.神经管畸形的病因探讨及预防.中国优生与遗传杂志,2001,9(2):88-89.
[11]J C S Dean,H hailey,S J Moore,et al.Long term health and neuro development in children exposed to antiepileptic drugs before birth.Journal of Medical Genetics,2002;39:251-259.
[12]Norgard B,Puho E,Czeizel AE,et al.Aspirinuse during early pregnancy and the risk of congenital abnormalities:apopulation-based case-control study.Am J Obstet Gynecol,2005,192(3):992-923.
[13]Loeken MR.Current perspectives on the causes of neuraltube defects resulting form diabetic pregnancy.Am J Med Genet C Semin Med Genet,2005;135(1):77-87.
[14]Snell LH,Haughey BP,Buck G,Marecki MA.Metabolic crisis:hyperemesis gravidarum.J Perinat Neonatal Nurs.1998 Sep;12(2):26-37.
[15]吴艳乔,张迅,包广泽,等.我国南方神经管缺陷病因学初探.中华医学遗传学杂志,1994:11(4):210.
[16]Czeizel Ae,Dobo M,Vargha P.Hungarian cohort-controlled trial of periconceptional multivitamin supplementation shows a reduction incertain congenital abnormalities.Birth Defects Res A Clin Mol Teratiol,2004,70(1):853-861.
[17]孙庆芝,柏松,崔炼,等.长期饮酒对男性生殖系统功能影响.沈阳医学院报,1999:1(1):36-39.
[18]李常惠,尚涛,田崇阳.309例神经管缺陷围产儿相关因素分.中国妇幼儿保健,2004:12(19):69-71.
[19]Wennborg H,Magnusson LL,Bonde JP,et al.Congenital malformations related to maternal exposure to specific agents in biomedical research laboratories.J Occup Environ Med,2005;47(1):11-19.
[20]Logman JF,deVries LE,Hemels ME,et al.Patrnal organi csolvent exposure and adverse pregnancy outcomes:ameta-analysis.Am J Ind Med,2005;47(1):37-44.
[1]Hibbard ED,Smitheiis RW.Folic acidmetabolism and human embryopathy.Lancet,1995;345(12):149-151.
[2]Goyett P,Sumner JS,Frosstp,et al.Human methylenetetrahydrofolate reductase:isolation of cDNA,mapping and mutation identification.Nat Gentet,1994;7(4):551.
[3]Steegers-Theunissen RPM,Boers GHJ,Trijbels FJM,et al.Maternal hyperhomocysteinemia:a risk factor for neural-tube defects.Metabolism,1991;43:1475-1480.
[4]Mills JL,McPanlin JM,Kirke PN,et al.Homocysteine metabolism in pregnancies complicated by neural-tube defects.Lancet,1995;345:149-151.
[5]朱慧萍,李竹.中国人MTHFR基因多态性与神经管畸形遗传易感性遗传.2000:22(4):236-238.
[6]郑冬梅,程丽坤,薛雅丽,等.MTHFR基因多态与神经管缺陷的关系哈尔滨医科大学学报.2001:35(2):113-115.
[7]赵如冰,朱慧萍,刀京晶.胱硫脒B合酶基因多态性与神经管畸形的关系研究.卫生研究,2000:29(1):50-51
[8]MotulskyAG,Nutritional ecogenetics:homocysteine-related arteriosclerotic vascular disease,neural tube defects,and folic acid.Am J Hum Genet,1996;58:17
[9]李勇,李竹,陈星,等.同型半胱氨酸诱发鸡胚神经管畸形及叶酸的保护作用.卫生研究,1998:27(6):372-376
[10]Frosst P,Blom HJ,Milos R,et al.A candidate genetic risk factor for vascular disease:a common mutation in methylenetetrahydrofolate reductase.Nat.Genet.1995;10:111-113
[11]Whitehead AS,Gallagher P,Mills JL.et al.A genetic defect in 5,10-methylenetetrahydrofolate reductase in neural tube defects.Q JM, 1995,88:763-766.
[12]Molly AM.Folate bioavailability and health.Int J Vitam Nutr Res 2002;72(1):46-52.
[13]Angchaisuksiri P,Pingsuthiwong S,Sura T,et al.Prevalence of the C677T methylenetetra- hydrofolate reductase mutation in Thai patients with deep vein thrombosis.Acto Haematol,2000;103:191-196.
[14]Fletcher O,Keosling AM.MTHFR association with vascular disease? Hum Genet 1998;103(1) 11-12.
[15]梁剑宁,陈盛强.143例正常人亚甲基四氢叶酸还原酶基因的检测.广州医学院学报.2002:30(1):38-40.
[16]裴丽君,朱慧萍.中国汉蒙两族人群MTHFR基因热敏感性多态性分布的比较.遗传,2000:22(6):369-371.
[1]Cabrera RM,Hill DS,Etheredge AJ,et al.Investigations into the etiology of neural tubed efects.Birth Defects Res CEmbryo Today,2004;72(4):330-344.
[2]代礼,朱军,周光萱,等.1996-2000年全国神经管缺陷的动态监测.中华预防医学杂志,2002:36(6):402-405.
[3]肖坤蚵.国内井出生缺暗概况.实用妇产科杂志,1989:5(1):1-3.
[4]李竹,李橙.中国妇女妊娠前后单纯服用叶酸 对神经管畸形的预防效果.中华医学杂志,2004:7(7):493-497.
[5]王巧梅,叶馥莉.神经臂畸形的预防.中国优生与遗传杂志,2001:8(1):9-10.
[6]秦新华.妇女增补叶醺预防神经管畸形推广工作信息[C].北京:北京医科大学-美国疾病控树中心合作项目办公室(项目通讯),1998:(1):12-13.
[7]CDC,Recommedation for the use of folic acid to reduse the number of cases of spina bifida and other neural tube defects MMWR,1992,41:1-7.
[8]高树生,洪渝,刘月旺,等.正常妊娠叶酸和维生素B12水平的动态变化.中华围产医学杂志,2002:5(1):56-57.
[9]Brown JE,Jacobs DR,Hartman TJ,et al.Predictors of Red cell folate level in women attending pregnancy.JAMA,1997;277:548.
[10]王竹.部分食物中叶酸含量和北京居民叶酸摄入量.营养学报2001:23(1).88-90.
[11]Itikala PR,Watkins ML,Mulinare J,et al.Maternal multivitamin use and orofacial clefts in offspring.Teratology,2001;63(2):79-86.
[12]任爱国,张乐,李智文,等.围孕期预防胎儿神经管畸形增补叶酸的剂量和安全性.中国生育健康杂志,2004:15(6):35-37.
[13]Scholl TO,Johnson WG.Folic Acid:influence of outcome of pregnancy.Am J Clin Nutr.2000,71(suppl):1295-1303.
[14]Parul Christian,Subarna KK,Joanne Katz,et al.Effects of alternative maternal micronutrient supplements on low birth weight in rural Nepal: double blind randomised community trial.BMJ,2003;32(6)6:115-9.
[15]陈利,桂宝芬,张丽萍,等.云南省用叶酸预防先天出生缺陷的现状和对策.中国初级卫生保健,2003:17(4):41-43
[16]Health Education Authority.Changing preconceptions,Vol 2.Research report London:HEA,1998.
[17]Scholl TO,Hediger ML,schall JI,et al.Oietary and serum folate:their influence on the outcome of pregnancy..Ame J Clin Nutr,1996;63(4):520
[18]孙红,王留娣.孕期血清叶酸水平与早产、婴儿出生体重的关系.重庆医学,2002;31(7):595-596.
[19]Wickremasinghe VP,Prageeth PP,Pulleperuma DS,et al.Preconceptional care of women at booking visit at De Soysa Maternity Hospital and Castle Street Hospital for Women.Ceylon Med J.2003;48(3):77-9.
[20]De Wals P,Rusen IO,Lee NS,et al.Trend in prevalence of neural tubedefects in Quebec.Birth Defects Res Part A Clin Mol Teratol.2003;67(11):919-23.
[21]石杭.面粉中适量添加营养素以增加营养 环球时报,2003,11月
[1]HOFFMAN JI,KAPLAN S.The incidence of congenital heart disease.J Am Coll Cardiol,2002:39(12):1890-1900.
[2]BURKI MK,BABAR GS.Prevalence and pattern of congenital heart disease in Hazara.J Ayub Med Coll Abbottabad,2001:13(1):16-18.
[3]杨江帆,许月珍,李萍,等.嘉兴市20436例新生儿先天性心脏病流行病学调查.中华儿科杂志,1997:35(8):417-420.
[4]GOLDMUNTZ E.The epidemiology and genetics of congenital heart disease.Clin Perinatol,2001:28(1):1210.
[5]GREENE K,PRIESTLEY MD,WATERS J,etal.Detailed mapping of a congenital heart disease gene in chromosome 3p25.J Med Genet,2000:37(8):581-587.
[6]GELB BD.Recent advances in the understanding of genetic causes of congenital heart defects.Front Biosci,2000;5:D321-333.
[7]GELB BD.Genetic basis of syndromes associated with congenital heart disease.Curt Opin Cardiol,2001:16(3):188-194.
[8]VAUGHAN CJ,BASSON CT.Molecular determinants of atrial and ventricular septal defects and patent ductus arteriosus.Am J Med Genet,2000;97(4):304-309.
[9]LI D,AHMAD F,GARDNER MJ,etal.The locus of a novel gene responsible for arrhythmogenic right-ventricul ardysplasia characterized by early on set and high penetrance maps to chromosome 10p12-p14.Am J Hum Genet,2000;66(1):148-156.
[10]BAMFORD RN,ROESSLER E,BURDINE RD,etal.Loss-of-function mutations in the EGF-CFC gene CFClare associated with human left-right laterality defects.Nat Genet,2000;26(3):365-369.
[11]SHI YR,HSIEH KS,WU JY,etal.Molecular analysis of syndromic congenital heart disease using short tandem repeat markers and semiquantitative polymerase chain reaction method.Pediatr Int,2002;44(3):2642268.
[12]GOLDMUNTZ E,GEIGER E,BENSON DW,etal.Nkx2.5 mutations in patients with tetralogy of fallot.Circulation,2001;104(21):2565-2568.
[13]ELDADAH ZA,HAMOS HA,BIERY NJ,et al.Familial tetralogy of fallot caused by mutation in the jaggedl gene.HumMol Genet,2001;10(2):163-169.
[14]SCHOTT JJ,BENSON DW,BASSON CT,et al.Congenital heart disease caused by mutations in the transcription factor NKX2-5.Science,1998;281:108-111.
[15]王晓明,张国成,韩美玉.B19病毒对先天性心脏病先天感染的探证及电镜观察.第四军医大学学报,2001:22(4):340-343.
[16]LOFFREDO CA,SILBERGELD EK,FERENC ZC,et al.Association of transposition of the great arteries in infants with maternal exposures to herbicides and rodenticides.Am J Epidemiol,2001;153(6):529-536.
[17]BOTTO LD,LOFFREDO C,SCANLONKS,et al.Vitamin A and cardiacout flow tract defects.Epidemiology,2001;12(5):491-496.
[18]BOTTO LD,MULINAR EJ,ERICKSON JO.Occurrence of congenital heart defects in relation to maternal multivitamin use.Am J Epidemiol,2000;151(9):878-884.
[19]岳凤珍,高秉仁.先天性心脏病家系的遗传学研究.中国优生优育,2001:12(2):57261.
[1]宋森涛,朱梁,王文静,等.应用SELDI-TOF-MS技术分析肝癌血清差异表达蛋白.实用癌症杂志,2004,19(6):601-604.
[2]邓昊,吴人亮,陈莹,等.应用组织芯片技术检测胃癌组织中PTEN、Survivin和p21ras蛋白的表达.华中科技大学学报(医学版),2006,35(3):284-287.
[3]Christophe Rosty,Laurence Christa,Scott Kuzdzal,et al.Identification of hepatocarcinoma-intestine-pancreas/pancreatitis-associated protein I as a biomarker for pancreatic ductal adenocarcinoma by protein biochip technology.Cancer research,2002,62:1868-1875.
[4]高春芳,赵光,宋国英,等.用飞行质谱技术筛选结直肠癌患者中特异性生物标志物的临床意义.中华检验医学杂志,2003,26(11):658-661.
[5]王全晖,高春芳,王秀丽,等.利用SELDI-TOF质谱技术分析大肠癌患者血清蛋白质谱的变化.中国病理生理杂志,2005,21(10):1896-1900.
[6]吴登龙,王文静,关明,等.表面增强激光解吸/离子化质谱蛋白质芯片技术在筛选肾癌患者尿液标记物中的应用.中华医学杂志,2004,84(13):1092-1095.
[7]Vlahou A,Schellhammer PF,Mendrinos S,et al.Development of a Novel Proteomic Approach for the Detection of Transitional Cell Carcinoma of the Bladder in Urine.Am J Pathol,2001,158(4):1491-1502.
[8]Wright GL,Cazares LH,Leunq SM,et al.Proteinchip(R)surface enhanced laser desorption/ionization(SELDI) mass spectrometry:a novel protein biochip technology for detection of prostate cancer biomarkers in complex protein mixtures.Prostate cancer Prostatic Dis,1999,2(5/6):264-276.
[9]Paweletz CP,Trock B,Pennanen M,et al.Proteomic patterns of nipple aspirate fluids obtained by SELDI-TOF:potential for new biomarkers to aid in the diagnosis of breast cancer.Dis Markers,2001,17(4):301-307.
[10]戴淑真,刘海霞,王斌,等.SELDI蛋白芯片技术筛选卵巢癌血清肿瘤标志物的研究.实用癌症杂志,2006,21(1):42-45.
[11]Wong YF,Cheung TH,Lo KW,et al.Protein profiling of cervical cancer by protein-biochips:proteomic scoring to discriminate cervical cancer from normal cervix.Cancer Lett,2004,211(2):227-234.
[12]Yang EC,Guo J,Diehl G,et al.Protein expression profiling of endometrial malignancies reveals a new tumor marker:chaperonin 10.J Proteome Res,2004,3(3):636-643.
[13]廖萍,王文静,朱佩云,等.SELDI-TOF-MS技术检测肺腺癌血清生物标志物.中国肿瘤,2006,15(4):258-261.
[14]Cho CS,Yip TT,Christine Y,et al.Serum protein chip profiling can identify new protein markers in the diagnosis of relapse 0f nasopharyngeal carcinoma.Proteomi cs,2002,(33):979-981.
[15]张妍,刘华林,王斌,等.利用SELDI-TOF-MS技术研究巨细胞病毒感染致婴儿肝炎综合征的血清蛋白标志物.世界华人消化杂志,2005,13(21):2549-2553.
[16]Zhang L,Yu W,He T,et al.Contribution of human alpha-defensin 1,2,and 3to the anti-HIV-1 activity of CD8 antiviral factor.Science,2002,298(5595):995-1000.
[17]Thulasiraman V,McCutchen-Maloney SL,Motin VL,et al.Detection and identifica- tion of virulence factors in Yersinia pestis using SELDI ProteinChip system.Biotechniques,2001,30(2):428-432.
[18]Seo GM,Kim SJ,Chai YG.Rapid profiling of the infection of Bacillus anthracis on human macrophages using SELDI-TOF mass spectroscopy.Biochem Biophys Res Commun,2004,325(4):1236-1239.
[19]Papadopoulos MC,Abel PM,Aqranoff D,et al.A novel and accurate diagnostic test for human African trypanosomiasis.Lancet,2004,363(9418):1358-1363.
[20]Kang X,Xu Y,Wu X,et al.Proteomic Fingerprints for Potential Application to Early Diagnosis of Severe Acute Respiratory Syndrome.Clin Chem,2005,51(1):56-64.
[21]魏晓真.利用飞行质谱法对急性心肌梗死血清标志物的研究.中国急救医学,2004,24(10):715-717.
[22]McBride MW,Graham D,Delles C,et al.Functional genomics in hypertension.Current Opinion in Nephrology and Hypertension,2006,15(2):145-151.
[23]Davies H,Lomas L,Austen B.Profiling of amyloid beta peptide variants using SELDI Protein Chip arrays.Biotechniques,1999,27(6):1258-1261.
[24]Wadsworth J.T,Somers K.D,Cazares L.H,et al.Serum protein profiles to identify head and neck.Clinical Cancer Research,2004,10(5):1625-1632.
[1]Cabrera RM,Hill DS,Etheredge AJ,et al.Investigations into the etiology of neural tube defects.Birth Defects Res C Embryo Today,2004;72(4):330-344.
[2]代礼,朱军,周光萱,等.1996-2000年全国神经管缺陷的动态监测.中华预防医学杂志,2002:36(6):402-405.
[3]谢妮,陈利玉,戴橄,等.人巨细胞病毒AD169株引起小鼠脑部畸形的初步探讨.湖南医科大学学报,2003:28(3):243-246.
[4]宋丽,路爱芝,朱庆义.神经管畸形的病因探讨及预防.中国优生与遗传杂志,2001:9(2):88-89.
[5]Tsuda T,Yoshida K,Ohashi S,et al.Arthrogryposis,hydranencephaly and cerebellar hypoplasia syndrome in neonatalcal vesresul ring form intrauterine infection with Aino virus.VetRes,2004;35(5):531-538.
[6]J C S Dean,H halley,S J Moore,et al.Long term health and neurodevelopment in children exposed to antiepileptic drugs before birth.Journal of Medical Genetics,2002,39:251-259.
[7]李勇,王维林,袁正伟,等.脊柱裂动物模型制作与胚胎发生缺制探讨.中华小儿外科杂志,2004:25(5):438-259.
[8]Norgard B,Puho E,Czeizel AE,et al.Aspirinuse during early pregnancy and the risk of congenital abnormalities:apopulation-based case-control study.Am J Obstet Gynecol,2005;192(3):992-923.
[9]Wennborg H,Magnusson LL,Bonde JP,et al.Congenital malformations related to maternal exposure to specific agents in biomedical research laboratories.J Occup Environ Med,2005;47(1):11-19.
[10]Logman JF,deVries LE,nemels ME,et al.Patrnal organic solvent exposure and adverse pregnancy outcomes:ameta-analysis.Am J Ind Med,2005;47(1):37-44.
[11]申华,冯杏.111例神经管畸形分析与预防对策的研究.中国优生与遗传杂 志,2002;10(1):107-118.
[12]Humpf HU,Voss KA.Effects of thermal food processing on the chemical structure and toxicity of fumonisin mycotoxins.Mol Nutr Food Res,2004,48(4):225-269.
[13]于丽,管英俊,李如江,等.高温致神经管畸形中bc12和bax变化的动物实验研究.潍坊医学院学报,2003,225(1):18-20.
[15]Moretti ME,Bar-Oz B,FriedS,et al.Maternal hyperthermia and the risk for neural tube defects in offspring:systematic review and meta-analysis.Epidemolgy,2005,16(2):216-219.
[16]Larsson L,Lindqvist PG.Low-impact exercise during pregnancy-a studyofsafety.ActaObstedGynecolScand,2005,84(1):24-38.
[17]Vieira AR,Castillotaucher S.Influence of maternal age on the risk for neural tube defects,ametaanalysis.Rey Med Chil,2005,133(1):62-70.
[18]Kazaura M,Lie RT,Skjaerven R,et al.Paternal ageand the risk of birth defects in Norway.Ann Epidemiol,2004,14(80):566-570.
[19]王东,于向民,李玲,等.被动吸烟诱导金黄地鼠神经管形成过程中细胞过度死亡.中国优生与遗传杂志,2005,13(2):115.
[20]Loeken MR.Current perspectives on the causes of neural tube defects resulting form diabetic pregnancy.Am J Med Genet C Semin Med Genet,2005,135(1):77-87.
[21]Ray JG,Wyatt PR,Vermeulen MJ,et al.Greater maternal weigh and the ongoing risk of neural tube defects after folic acid flour fortification.Obstet Gynecol,2005,105(2):261-265.
[22]Czeizel Ae,Dobo M,Vargha P.Hungarian cohort-controlled tria of periconceptional multivitamin supplementation shows a reduction incertain congenital abnormalities.Birth Defects Res A Clin Mol Teratiol,2004,70(1):853-861.
[23]shaw GM,Carmichalel SL,Yang W,et al.Periconceptional dietary intake of myo-inostiol and neural tube defects in offspring.Birth Defects Res A Clin Mol Teratol,2005,73(3):184-187.
[24]Ulman C,Taneli F,Oksel F,et al.Zinc-deficient sprouting blight potatoes and their possible relation with neural tube defects.Cell Biochen Funct,2005,23(1):69-72.
[25]carrillo-Ponce MdeL,Martinez-OrdazVA,Yelasco-Rodriguez VM,et al.Serum lead,cadium,and zinc levels in new borns with neural tube defects from apolluted zone in Mexico.Reprod Toxicol,2004,19(2):149-154.
[26]Cengiz B,Soyemezf,Ozturk E,et al.Serum zinc,selenium,copper,and lead levels in women sith second-trimester induced abortion resulting form neural tube defects:a preliminary study.Biol Trace Elem Res,2004,97(3):225-235.
[27]BlancoMunoz J,Lacasana M,BorjaAburto YH,et al.Socioeconomic factors and the risk of anencephaly in a Mexican population:a case-control study.Public Health Rep,2005,120(1):39-45.
[28]李常惠,尚涛,田崇阳.309例神经管缺陷围产儿相关因素分.中国妇幼儿保健,2004,12(19):69-71.
[1]代礼,朱军,周光萱,等.1996-2000年全国神经管缺陷的动态监测.中华预防医学杂志,2002:36:402-405.
[2]Mills JL,McPanlin JM,Kirke PN,et al.Homocysteine metabolism in pregnancies complicated by neural tube defects.Lancet,1995;345:149-151.
[3]Weisberg IS,Tran P,Christensen B,et al.A second genetic polymorphism in methylenetetrahydrofolate reductase associated with decreased enzyme activity.Mol Genet Metab,1998;64:169-172.
[4]Frosst P,Blom HJ,Milos R,et al.A candidate genetic risk factor for vascular disease:a common mutation in methylenetetra-hydrofolate reductase.Nat Genet,1995;10:111-113.
[5]Yamada K,Chen Z,Rozen R,et al.Effect of conlnlon polymorphisms on the properties of recombinant human methylenetetrahydrofolate reductase.Proc Nati Acad Sci,2001;98:14853-14858.
[6]De Marco P,Calevo MG,Moroni A,et al.Study of MTHFR and MS polymorphisms as risk factor for NTDs in the Italian population.J Hum Genet,2002:47:319-324.
[7]郭晓霞,高原原,詹思延,等.5,10-亚甲基四氢叶酸还原酶多态性与神经管畸形的病例对照研究.疾病控制杂志,2000:4:217-219.
[8]Hansen DK,Barbes SA,Grafton TF,et al.Antisense modulation of 5,10-methylenetetrahydrofolate reductase expression produces neural tube defects in mouse embryos.Reprod Toxical,2001;15:21-29.
[9]Gonzalez-Herrera L,Orozco-Orozco L,Del Angel R,et al.Frequency of the thermolabile variant C677T in the MTHFR gene and 1 k of association with neural tube defects in the State of Yucatan,Mexico.Clin Genet,2002;62:394-398.
[10]Williamson R.Prevention of birth defects:folic acid.Biol Res Nurs,2001;3:33-38.
[11]李竹,陈新,赵平,等.妇女增补叶酸预防神经管畸形推广研究五年成果和工作总结.中国公共卫生,2001:17:725-727.
[12]Molly AM.FOlate bioavailability and health.Int J Vitam Nutr Res,2002;72:46-52.
[13]Steergers-Theunisen RP,Boers GH,Tribels FJ,et al.Maternal hyperhomoeysteineia:a risk factor for neural tube defect.Metabo lism,1994;43:1475-1480.
[14]李勇,李竹,陈星,等。同型半胱氨酸诱发鸡胚神经管畸形及叶酸的保护作用.卫生研究,1998:27:372-376.
[15]Jacques PF,Selhub J,Boston AG,et al.The effect of folie acid fortification on plasma folate and total homocysteine concentrations.N Engl J Med,1999,340:1449-1454.
[16]Rader JI.FOlie acid fortification,folate status and plasma homocysteine.J Nutr,2002,132:2466-2470.
[17]Stephane B,Bruno T,Estelle C,et al.Hyperhomocysteinaemia,folate an d vitamin B12 in unsupplemented haemodialysis patients:effect of oral therapy with folie acid and vitamin B_12.Nephrol Dial Transplant,2002,17:455-461.
[18]Guttormen AB,Ueland PM,Nesthus L,et al.Determinants and vitamin responsiveness of intermediate hyperhomocysteinemia.The Hordaland Homocysteine Study.J Clin Invest,1996;98:2174.
[19]Weisberg IS,Jacques PF,Selhub J,et al.The 1298-C polymorphism in methylenetetrahydrofolate reductase(MTHFR):in vitro expression and association with homocysteine.Atherosclerosis,2001;156:409-415.
[20]Hanson NQ,Aras O,Yang F,et al.C677T and A1298C polymorphisms of the methylenetetrahydrofolate reductase gene:incidence and effect of combined genotypes on plasma fasting and post-methionine load homocysteine in vascular disease.Clin Chem,2001;47:661-666.
[21]Maria LS,Maire R,Maritta S,et al.Polymorphisms of key enzymes in homocysteine metabolism affect diet responsiveness of plasma homocysteine in healthy women.J Nutr,2001;131:2643-2647.
[22]郝玲,刘明珠,刘晓慧,等.血浆同型半胱氨酸与叶酸、维生素Blz及还原酶的关系.中华预防医学杂志,2000,34:22-24.